{
  1 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN +"
          2 : "NN + + conj NN"
          3 : 23
          4 : 
            {
              1 : "The aim of this study was to assess the effect of drug1 , the intake of saturated fatty acids ( SFA ) , and drug2 on serum lipid levels in Lithuanian adult population . "
              2 : "CONCLUSIONS : drug1 , SFA intake , and drug2 were found to be associated with blood lipid levels in Lithuanian adult population . "
              3 : "CONCLUSIONS : We found no consistent association between drug1 and drug2 . "
              4 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . "
              5 : "Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 was observed . "
              6 : "In 2001 , we published the first significant evidence of a genetic association between drug2 and a synonymous coding SNP drug1 in the androgen receptor gene , AR . "
              7 : "The aim of this study was to assess the effect of drug1 , the intake of drug2 , and drug3 in Lithuanian adult population . "
              8 : "drug1 , SFA intake , and drug2 were found to be associated with drug3 in Lithuanian adult population . "
              9 : "Multivariate analysis showed association between drug1 and drug3 , independently from the effect of drug2 . "
              10 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 +"
              2 : "drug0 + conj drug0 +"
              3 : "drug0 + conj drug0 +"
              4 : "drug0 + conj drug0 +"
              5 : "drug0 + conj drug0 +"
              6 : "drug0 + + conj drug0"
              7 : "drug0 + conj drug0 +"
              8 : "drug0 + conj drug0 +"
              9 : "drug0 + conj drug0 +"
              10 : "drug0 + + conj drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NN +"
          2 : "NN + + conj NN"
          3 : 340
          4 : 
            {
              1 : "drug1 : Concomitant administration of drug2 ORAL and drug3 resulted in decreased clearance of drug4 and significant increases in drug5 plasma levels ( total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL ) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours . "
              2 : "Therefore , concomitant use of drug1 and drug2 is contraindicated . "
              3 : "drug1 : Concomitant administration of drug2 and some drug3 has been reported to reduce the clearance of drug4 , enhancing the toxicity of drug5 . "
              4 : "drug1 : Sporadic cases of seizures have been reported during concomitant use of drug2 and drug3 ( drug4 , drug5 ) . "
              5 : "Concurrent administration of drug1 and drug2 , which competes for tubular secretion , has been shown to increase the plasma half-life of drug3 . "
              6 : "Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another drug1 and drug2 but may be seen after several months . "
              7 : "For these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with drug1 and a drug2 do not outweigh the risks of severe myopathy , rhabdomyolysis , and acute renal failure . "
              8 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 "
              9 : "Marked symptomatic orthostatic hypotension has been reported when drug1 and organic drug2 were used in combination . "
              10 : "Therefore , when drug1 and drug2 are used concomitantly , the patient should be observed closely to determine if the desired effect of the drug3 is obtained . ) "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 +"
              2 : "drug0 + conj drug0 +"
              3 : "drug0 + conj drug0 +"
              4 : "drug0 + conj drug0 +"
              5 : "drug0 + conj drug0 +"
              6 : "drug0 + conj drug0 +"
              7 : "drug0 + conj drug0 +"
              8 : "drug0 + conj drug0 +"
              9 : "drug0 + conj drug0 +"
              10 : "drug0 + conj drug0 +"
            }
        }
    }
  2 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN"
          3 : 15
          4 : 
            {
              1 : "OBJECTIVE : drug1 has been associated with drug2 and athero-thrombosis however the association with drug3 ( AAA ) has not been previously examined . "
              2 : "COMT genotype drug1 was associated with drug2 in the first 45 min in the PACU ( p = .04 ) . "
              3 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . "
              4 : "RESULTS : drug2 was significantly associated with SNP drug1 ( P ( allele ) = 3.6x10 ( -3 ) ; OR = 1.56 ; 95 % c.i. : 1.12-2.15 ) and HLA-DRB1 * 1501-DQB1 * 0602 haplotype ( P ( positivity ) = 9.2x10 ( -11 ) ; OR = 3.97 ; 95 % c.i. : 2.55-6.19 ) . "
              5 : "drug1 , a SNP located between CPT1B and CHKB , was associated with drug3 in Japanese ( drug2 [C ] , odds ratio ( OR ) = 1.79 , combined P = 4.4 x 10 ( -7 ) ) and other ancestry groups ( OR = 1.40 , P = 0.02 ) . "
              6 : "We utilised statistical methods appropriate for the categorical nature of the phenotype and familial structure of the cohort , and determined that whilst SNP drug1 was strongly associated with drug2 ( P < 0.0001 ) , the GGN triplet repeat was not ( P = 0.13 ) . "
              7 : "In the present study , we investigated whether drug1 was associated with drug2 in predominantly middle-aged persons . "
              8 : "In the UK National Registry dataset , drug1 was significantly associated with drug2 in the male subgroup ; significant SNP-by-smoking interactions were observed . "
              9 : "A candidate SNP drug1 in drug2 was significantly ( p=0.015 ) associated with drug3 . "
              10 : "The SNP drug1 was nominally associated with drug2 in the initial ( p = 0.08 ) and two replication sample sets ( p = 0.05 and 0.06 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep drug0"
              2 : "associated + ppmod drug0 + dep drug0"
              3 : "associated + ppmod drug0 + dep drug0"
              4 : "associated + dep drug0 + ppmod drug0"
              5 : "associated + ppmod drug0 + dep drug0"
              6 : "associated + ppmod drug0 + dep drug0"
              7 : "associated + ppmod drug0 + dep drug0"
              8 : "associated + ppmod drug0 + dep drug0"
              9 : "associated + ppmod drug0 + dep drug0"
              10 : "associated + ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN"
          3 : 91
          4 : 
            {
              1 : "drug1 should not be administered concomitantly with drug2 , drug3 , drug4 , drug5 , or drug6 . "
              2 : "Serum drug1 levels should be monitored frequently if drug2 is administered concomitantly with drug3 . "
              3 : "Blood levels of drug1 increased 24 % when drug2 was coadministered with drug3 ( nonselective inhibitor of cytochrome P-450 ) for 7 days , and decreased 28 % with coadministration of drug4 ( potent inducer of cytochrome P-450 ) for 7 days . "
              4 : "Clearance of drug1 decreased by about 27 % when drug2 was administered intravenously concomitantly with drug3 . "
              5 : "drug1 should not be used with other drug2 . "
              6 : "Therefore , if drug1 is co-administered with drug2 , its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drug3 should to monitored . "
              7 : "drug1 : When drug2 ( 50 mg tid ) was administered concomitantly with drug3 for two weeks , drug4 plasma concentrations increased by 98 % and prothrombin times were prolonged . "
              8 : "However , because some drug1 have been reported to enhance the effects of drug2 or its derivatives , prothrombin time or other suitable anticoagulation test should be monitored closely if a drug3 is administered with drug4 or its derivatives . "
              9 : "Caution should be used if drug1 is administered simultaneously with drug2 . "
              10 : "Caution should be used if drug1 is administered concomitantly with drug2 . "
            }
          5 : 
            {
              1 : "administered + ppmod drug0 + dep drug0"
              2 : "administered + ppmod drug0 + dep drug0"
              3 : "coadministered + ppmod drug0 + dep drug0"
              4 : "administered + ppmod drug0 + dep drug0"
              5 : "used + ppmod drug0 + dep drug0"
              6 : "co-administered + ppmod drug0 + dep drug0"
              7 : "administered + ppmod drug0 + dep drug0"
              8 : "administered + ppmod drug0 + dep drug0"
              9 : "administered + ppmod drug0 + dep drug0"
              10 : "administered + ppmod drug0 + dep drug0"
            }
        }
    }
  3 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN"
          3 : 10
          4 : 
            {
              1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . "
              2 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [OR ] 0.61 and OR 2.01 , respectively ) . "
              3 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . "
              4 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . "
              5 : "As expected , the T risk allele of drug1 was associated with higher drug2 ( p = 0.01 ) . "
              6 : "We confirmed that the risk allele of drug1 is associated with drug2 and a drug3 . "
              7 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . "
              8 : "The T allele of drug1 was significantly associated with decreased drug2 ( Studies II , III ) . "
            }
          5 : 
            {
              1 : "observed + ppmod drug0 + dep ld ppmod drug0"
              2 : "associated + ppmod drug0 + dep genotype ppmod drug0"
              3 : "associated + ppmod drug0 + dep genotype ppmod drug0"
              4 : "associated + ppmod drug0 + dep genotype ppmod drug0"
              5 : "associated + ppmod drug0 + dep allele ppmod drug0"
              6 : "associated + ppmod drug0 + dep allele ppmod drug0"
              7 : "replicated + dep susceptibility ppmod drug0 + ppmod drug0"
              8 : "associated + ppmod drug0 + dep allele ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN"
          3 : 14
          4 : 
            {
              1 : "drug1 , drug2 , drug3 , and drug4 The in vitro binding of drug5 to plasma proteins is only slightly reduced by drug6 ( 99.5 % control vs 99.3 % ) when drug7 plasma concentrations reach 5 to10 m g/mL . "
              2 : "drug1 : Studies in animals demonstrate that the acute toxicity of drug2 is enhanced by the drug3 drug4 . "
              3 : "As with other drug1 , the antihypertensive effect of drug2 may be blunted by the drug3 drug4 "
              4 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . "
              5 : "The action of drug1 is potentiated by drug2 . "
              6 : "Response to drug1 may be enhanced by drug2 . "
              7 : "drug1 : drug2 is not recommended for use in patients who have received drug3 within 14 days because severe and unpredictable potentiation by drug4 has been reported with drug5 "
              8 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . "
              9 : "drug1 : As with other drug2 , the renal excretion of drug3 is inhibited by drug4 . "
              10 : "Pharmacodynamic Interactions : The CNS-depressant action of the drug1 of drugs may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , the drug7 , drug8 and drug9 , drug10 and the drug11 , and by other drug12 . "
            }
          5 : 
            {
              1 : "reduced + ppmod drug0 + dep drug0 ppmod drug0"
              2 : "enhanced + ppmod drug0 + dep toxicity ppmod drug0"
              3 : "blunted + ppmod drug0 + dep effect ppmod drug0"
              4 : "augmented + ppmod drug0 + dep effect ppmod drug0"
              5 : "potentiated + ppmod drug0 + dep action ppmod drug0"
              6 : "enhanced + ppmod drug0 + dep response ppmod drug0"
              7 : "reported + ppmod drug0 + dep potentiation ppmod drug0"
              8 : "enhanced + ppmod drug0 + dep action ppmod drug0"
              9 : "inhibited + ppmod drug0 + dep excretion ppmod drug0"
              10 : "potentiated + ppmod drug0 + dep action ppmod drug0"
            }
        }
    }
  4 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN"
          3 : 10
          4 : 
            {
              1 : "Although there was only moderate linkage disequilibrium between drug1 and the ApoE e4 defining SNP drug2 , we could not find an APOE-independent effect of drug3 on drug4 , either in cross-sectional or in longitudinal analyses . "
              2 : "The association of drug1 with the drug2 and drug3 combination could help to explain the contradictory results of previous studies . "
              3 : "The T allele of drug1 showed an association with borderline significance ( OR = 1.19 , 95 % C.I. = 1.01-1.42 , P = 0.04 ) , and the Cochran-Armitage test for trend revealed an allele dose-dependent association of drug2 with drug3 ( Ptrend = 0.04 ) . "
              4 : "Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 . "
              5 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . "
              6 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . "
              7 : "We did not detect any association of the drug1 with drug2 , "
              8 : "Comparison between allele and genotype frequencies of these SNPs in patients and controls showed marginal association for drug1 and drug2 with drug3 ( p = 0.063 , OR 1.982 , 95 % CI 1.128-3.485 ; p = 0.071 , OR 1.237 , 95 % CI 0.983-1.557 , respectively ) . "
              9 : "We studied the effect of TCF7L2 drug1 and drug2 genotypes on drug3 "
              10 : "We observed a significant association between the single-nucleotide polymorphism ( SNP ) drug1 and the microsatellite drug2 with drug3 in the Mexican sample "
            }
          5 : 
            {
              1 : "effect + ppmod drug0 + ppmod drug0"
              2 : "association + ppmod drug0 + ppmod drug0"
              3 : "association + ppmod drug0 + ppmod drug0"
              4 : "role + ppmod drug0 + ppmod drug0"
              5 : "role + ppmod drug0 + ppmod drug0"
              6 : "association + ppmod drug0 + ppmod drug0"
              7 : "association + ppmod drug0 + ppmod drug0"
              8 : "association + ppmod drug0 + ppmod drug0"
              9 : "effect + ppmod drug0 + ppmod drug0"
              10 : "association + ppmod drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN"
          3 : 91
          4 : 
            {
              1 : "Co-administration of drug1 with drug2 produced a 25 % increase in AUC and a 33 % increase in the Cmax of drug3 . "
              2 : "Limited clinical experience indicates that requirements for drug1 are reduced by 30 to 50 % for the first sixty ( 60 ) minutes following drug2 induction The concomitant use of drug3 with drug4 can significantly inhibit drug5 clearance and may increase the risk of prolonged or delayed respiratory depression . "
              3 : "Therefore , the combined use of drug1 with drug2 should generally be avoided . "
              4 : "drug1 and drug2 ( Hypertension ) - In clinical studies of patients with hypertension , the addition of drug3 50 to 100 mg to drug4 and drug5 increased mean serum potassium slightly ( about 0.09-0.13 mEq/L ) . "
              5 : "The administration of other drug1 with drug2 has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function . "
              6 : "Concomitant administration of drug1 with drug2 is contraindicated . "
              7 : "In a small ( n=30 ) combination study of drug1 with drug2 , a 2- to 3-fold elevation in liver enzymes was seen in 5 of 30 patients . "
              8 : "Simultaneous administration of drug1 with drug2 should be avoided . "
              9 : "The concomitant use of drug1 or drug2 with drug3 is not recommended . "
              10 : "drug1 : Use of drug2 with drug3 and other drug4 may increase receptor sensitivity and enhance antidepressant activity transient cardiac arrhythmias have been observed . "
            }
          5 : 
            {
              1 : "co-administration + ppmod drug0 + ppmod drug0"
              2 : "use + ppmod drug0 + ppmod drug0"
              3 : "use + ppmod drug0 + ppmod drug0"
              4 : "addition + ppmod drug0 + ppmod drug0"
              5 : "administration + ppmod drug0 + ppmod drug0"
              6 : "administration + ppmod drug0 + ppmod drug0"
              7 : "study + ppmod drug0 + ppmod drug0"
              8 : "administration + ppmod drug0 + ppmod drug0"
              9 : "use + ppmod drug0 + ppmod drug0"
              10 : "use + ppmod drug0 + ppmod drug0"
            }
        }
    }
  5 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NN conj NN"
          2 : "NN + ppmod NN conj NN + ppmod NN"
          3 : 9
          4 : 
            {
              1 : "Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 . "
              2 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . "
              3 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . "
              4 : "The consistent association between drug1 in TCF7L2 and drug2 in different ethnic groups , including the Japanese population , suggests that TCF7L2 is a common susceptibility gene for type 2 diabetes . "
              5 : "There was no association of drug1 with drug2 ( p = 0.98 ) , drug3 ( p = 0.89 ) , drug4 ( p = 0.32 ) or drug5 ( p = 0.92 ) . "
              6 : "Comparison between allele and genotype frequencies of these SNPs in patients and controls showed marginal association for drug1 and drug2 with drug3 ( p = 0.063 , OR 1.982 , 95 % CI 1.128-3.485 ; p = 0.071 , OR 1.237 , 95 % CI 0.983-1.557 , respectively ) . "
              7 : "We observed a significant association between the single-nucleotide polymorphism ( SNP ) drug1 and the microsatellite drug2 with drug3 in the Mexican sample "
            }
          5 : 
            {
              1 : "role + ppmod drug0 + ppmod drug0 conj drug0"
              2 : "role + ppmod drug0 conj drug0 + ppmod drug0"
              3 : "association + ppmod factor conj drug0 + ppmod drug0"
              4 : "association + ppmod tcf0l0 conj drug0 + ppmod drug0"
              5 : "association + ppmod drug0 conj drug0 + ppmod drug0"
              6 : "association + ppmod drug0 + ppmod drug0 conj drug0"
              7 : "association + ppmod drug0 + ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN conj NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN conj NN"
          3 : 27
          4 : 
            {
              1 : "drug1 and drug2 ( Hypertension ) - In clinical studies of patients with hypertension , the addition of drug3 50 to 100 mg to drug4 and drug5 increased mean serum potassium slightly ( about 0.09-0.13 mEq/L ) . "
              2 : "The concomitant use of drug1 or drug2 with drug3 is not recommended . "
              3 : "Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving drug1 metabolized similarly to drug2 or on the basis of in vitro studies with drug3 or other drug4 ( caution is recommended during coadministration with drug5 ) : Available data from clinical studies of drug6 other than drug7 suggest a possible drug interaction with drug8 for the following : drug9 , drug10 , drug11 such as drug12 and drug13 , and grapefruit juice . "
              4 : "Co-administration : Concomitant use of drug1 with drug2 , drug3 , and other drug4 may increase the risk of bleeding . "
              5 : "Coadministration of drug1 with oral drug2 or drug3 has resulted in elevated plasma concentrations of the latter two drugs . "
              6 : "drug1 / drug2 / drug3 / drug4 : Co-administration of drug5 with drug6 , drug7 , drug8 , and drug9 is likely to lead to an enhancement of effects . "
              7 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . "
              8 : "Coadministration of drug1 with other drug2 , drug3 , and drug4 may cause hypokalemia . "
              9 : "However , since drug1 , drug2 , and drug3 are all associated with gastrointestinal irritation , caution should be exercised in the concomitant use of drug4 or drug5 with drug6 . "
              10 : "Concomitant use of drug1 with drug2 , drug3 , drug4 , or other drug5 may have an additive effect . "
            }
          5 : 
            {
              1 : "addition + ppmod drug0 conj drug0 + ppmod drug0"
              2 : "use + ppmod drug0 + ppmod drug0 conj drug0"
              3 : "interaction + ppmod following conj drug0 + ppmod drug0"
              4 : "use + ppmod drug0 conj drug0 + ppmod drug0"
              5 : "coadministration + ppmod drug0 conj drug0 + ppmod drug0"
              6 : "co-administration + ppmod drug0 conj drug0 + ppmod drug0"
              7 : "administration + ppmod [e.g. conj drug0 + ppmod drug0"
              8 : "coadministration + ppmod drug0 conj drug0 + ppmod drug0"
              9 : "use + ppmod drug0 + ppmod drug0 conj drug0"
              10 : "use + ppmod drug0 conj drug0 + ppmod drug0"
            }
        }
    }
  6 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN conj NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN conj NN"
          3 : 6
          4 : 
            {
              1 : "The G/G homozygous genotype in COMT drug1 and A/A homozygous genotype in PLCH1 drug2 were associated with drug3 and drug4 , respectively ( odds ratio [OR ] 0.61 and OR 2.01 , respectively ) . "
              2 : "We found no association of the TCF7L2 genotypes with age at diagnosis , BMI or WHR , but the risk genotype at drug1 was associated with drug2 ( p = 0.001 ) , drug3 ( p = 0.0002 ) and drug4 model assessment of drug5 ( HOMA-R ; p = 0.012 ) in non-diabetic subjects . "
              3 : "We confirmed that the risk allele of drug1 is associated with drug2 and a drug3 . "
              4 : "In our case-control subjects , susceptibility to drug9 was replicated in TCF7L2 drug1 , CDKAL1 drug2 , drug3 , HHEX ( drug4 ) , IGF2BP2 ( drug5 and drug6 ) , CDKN2A/B ( drug7 ) , and SLC30A8 ( drug8 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 conj drug0 + dep genotype ppmod drug0"
              2 : "associated + ppmod drug0 conj drug0 + dep genotype ppmod drug0"
              3 : "associated + ppmod drug0 conj drug0 + dep allele ppmod drug0"
              4 : "replicated + dep susceptibility ppmod drug0 + ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN conj NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN conj NN"
          3 : 20
          4 : 
            {
              1 : "The absorption of drug1 may be affected by the simultaneous administration of indigestion remedies , drug2 or drug3 supplements . "
              2 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . "
              3 : "Pharmacodynamic Interactions : The CNS-depressant action of the drug1 of drugs may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , the drug7 , drug8 and drug9 , drug10 and the drug11 , and by other drug12 . "
              4 : "The action of the drug1 may be potentiated by drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , or other drugs that produce CNS depression . "
              5 : "The response to drug1 may be blunted by drug2 and drug3 which cause a rise in prolactin . "
            }
          5 : 
            {
              1 : "affected + ppmod administration conj drug0 + dep absorption ppmod drug0"
              2 : "enhanced + ppmod drug0 conj drug0 + dep action ppmod drug0"
              3 : "potentiated + ppmod drug0 conj drug0 + dep action ppmod drug0"
              4 : "potentiated + ppmod drug0 conj drug0 + dep action ppmod drug0"
              5 : "blunted + ppmod drug0 conj drug0 + dep response ppmod drug0"
            }
        }
    }
  7 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN conj NN +"
          2 : "NN + + conj NN conj NN"
          3 : 6
          4 : 
            {
              1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . "
              2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
              3 : "METHODS : We reviewed the literature relating to SNPs drug1 and drug2 and drug3 , and clinical and preclinical studies , which shed light on the mechanisms underlying these associations "
              4 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . "
              5 : "CONCLUSIONS : We have confirmed associations between drug3 and drug1 and drug2 . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 conj drug0 +"
              2 : "drug0 + + conj drug0 conj drug0"
              3 : "drug0 + conj drug0 conj drug0 +"
              4 : "drug0 + conj drug0 conj drug0 +"
              5 : "drug0 + + conj drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NN conj NN +"
          2 : "NN + + conj NN conj NN"
          3 : 2
          4 : 
            {
              1 : "Concurrent use of drug1 and drug2 or drug3 has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia . "
              2 : "Although drug1 or drug2 and drug3 may be useful in combination to control atrial fibrillation , their additive effects on AV node conduction can result in advanced or complete heart block . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 conj drug0 +"
              2 : "drug0 + conj drug0 conj drug0 +"
            }
        }
    }
  8 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN ppmod NN"
          3 : 5
          4 : 
            {
              1 : "Moreover , the T allele at drug1 was inversely associated with log-transformed , HOMA- % B ( beta=-0.07 , p=0.005 ) as a measure of drug2 , and drug3 ( beta=-0.06 , p=0.02 ) . "
              2 : "le of drug1 as also associated with increased prevalence of drug2 . "
              3 : "A-allele of drug1 was associated with an increased risk of drug2 regardless of smoking exposure ( pooled OR = 1.26 , 95 % CI 1.18-1.34 , p < 10⁻⁵ ) . "
              4 : "The T ( minor ) allele of the variant drug1 was significantly associated with a greater OR for drug2 adjusted for age , sex and BMI in logistic regression analysis : "
              5 : "Specifically , the same risk allele of single nucleotide polymorphism ( SNP ) drug1 that is associated with drug2 ( T allele ) has recently been associated with an increased risk of drug3 . "
            }
          5 : 
            {
              1 : "associated + ppmod measure ppmod drug0 + dep allele ppmod drug0"
              2 : "associated + ppmod prevalence ppmod drug0 + dep le ppmod drug0"
              3 : "associated + ppmod risk ppmod drug0 + dep a-allele ppmod drug0"
              4 : "associated + ppmod or ppmod drug0 + dep allele ppmod drug0"
              5 : "associated + ppmod risk ppmod drug0 + dep allele ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NN ppmod NN"
          3 : 11
          4 : 
            {
              1 : "drug1 Renal tubular transport of drug2 may be inhibited by concomitant administration of drug3 , potentially leading to increased plasma levels of drug4 . "
              2 : "drug1 and drug2 drug3 : Absorption of drug4 is impaired in the presence of drug5 . "
              3 : "The AUC of drug1 was increased 2.2-fold by coadministration of drug2 , a potent inhibitor of CYP3A4 , 400 mg daily for 5 days . "
              4 : "drug1 s : After repeated co-administration of drug2 , the AUC of drug3 was lowered by 28 % [90 % CI : 20-33 ] . "
              5 : "It is possible that the cardiovascular action of other drug1 could be enhanced by the addition of drug2 . "
              6 : "The clearance of drug1 may be increased with concurrent use of drug2 . "
              7 : "Plasma exposure of drug1 ( 10 mg BID ) was increased by 28 % following administration of drug2 ( 40 mg BID ) for 12 days , while plasma exposure of drug3 ( 40 mg BID ) was not substantially increased following administration of drug4 ( 10 mg BID ) for 12 days . "
              8 : "The oral bioavailability of drug1 is reduced by 60 % with coadministration of drug2 . "
              9 : "drug1 : Enhanced bone marrow suppression by drug2 and other drug3 has been reported among patients with neoplastic disease , except leukemia , in the presence of drug4 . "
              10 : "The anticoagulant effect of drug1 is enhanced by concurrent treatment with drug2 ( human ) in patients with hereditary antithrombin III deficiency . "
            }
          5 : 
            {
              1 : "inhibited + ppmod administration ppmod drug0 + dep transport ppmod drug0"
              2 : "impaired + ppmod presence ppmod drug0 + dep absorption ppmod drug0"
              3 : "increased + ppmod coadministration ppmod drug0 + dep auc ppmod drug0"
              4 : "lowered + dep auc ppmod drug0 + ppmod co-administration ppmod drug0"
              5 : "enhanced + ppmod addition ppmod drug0 + dep action ppmod drug0"
              6 : "increased + ppmod use ppmod drug0 + dep clearance ppmod drug0"
              7 : "increased + ppmod administration ppmod drug0 + dep exposure ppmod drug0"
              8 : "reduced + ppmod coadministration ppmod drug0 + dep bioavailability ppmod drug0"
              9 : "reported + ppmod presence ppmod drug0 + dep suppression ppmod drug0"
              10 : "enhanced + ppmod treatment ppmod drug0 + dep effect ppmod drug0"
            }
        }
    }
  9 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN com NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN com NN"
          3 : 4
          4 : 
            {
              1 : "Our data are compatible with the hypothesis of a complex role of drug1 in the drug2 pathogenesis , with positive and negative effects occurring concomitantly according to its expression levels and its protein-protein interactions largely unclarified . "
              2 : "There was evidence of association of drug1 genotype with drug2 in our open-label trial sample but not our placebo-controlled trial sample . "
              3 : "RESULTS : Despite sufficient power to detect associations at genome-wide significance thresholds across a range of ORs , our analyses did not support a role of drug1 or drug2 on drug3 susceptibility "
              4 : "In addition to these polymorphisms , meta-analysis confirmed the association of drug4 susceptibility with KCNJ11 drug1 , TCF7L2 drug2 , and HHEX drug3 . "
            }
          5 : 
            {
              1 : "role + ppmod pathogenesis com drug0 + ppmod drug0"
              2 : "association + ppmod drug0 + ppmod genotype com drug0"
              3 : "role + ppmod susceptibility com drug0 + ppmod drug0"
              4 : "association + ppmod susceptibility com drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN com NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN com NN"
          3 : 3
          4 : 
            {
              1 : "drug1 : The concomitant administration of drug2 with the drug3 drug4 has , on rare occasions , resulted in severe hypoglycemia . "
              2 : "This antagonistic effect of drug1 on drug2 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drug3 . "
              3 : "We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral drug1 cytotoxicity by drug2 . "
            }
          5 : 
            {
              1 : "administration + ppmod drug0 com drug0 + ppmod drug0"
              2 : "effect + ppmod natriuresis com drug0 + ppmod drug0"
              3 : "reduction + ppmod drug0 + ppmod cytotoxicity com drug0"
            }
        }
    }
  10 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN +"
          2 : "NN + + ppmod NN"
          3 : 4
          4 : 
            {
              1 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . "
              2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
              3 : "A candidate SNP drug1 in drug2 was significantly ( p=0.015 ) associated with drug3 . "
            }
          5 : 
            {
              1 : "drug0 + ppmod drug0 +"
              2 : "drug0 + ppmod drug0 +"
              3 : "drug0 + ppmod drug0 +"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN +"
          2 : "NN + + ppmod NN"
          3 : 21
          4 : 
            {
              1 : "Patients taking drug1 concomitantly with drug2 more commonly reported both weight gain and weight loss , compared with patients taking either medication alone . "
              2 : "drug1 : Concomitant administration of drug2 containing drug3 or drug4 with drug5 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug6 components . "
              3 : "Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug3 ( e. g. , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 ) , drug12 salts , drug13 , local drug14 , drug15 , and drug16 . "
              4 : "drug1 ( drug2 ) : The concomitant administration of a drug3 with a drug4 may increase the risks of CNS stimulation and convulsions . "
              5 : "drug1 with drug2 or drug3 and possibly other drug4 cause striking and sustained increases in the concentration of drug5 in the brain ; "
              6 : "The concomitant use of transdermal drug1 with drug2 or other potent 3A4 inhibitors such as drug3 , drug4 , drug5 , drug6 , drug7 , and nefazadone may result in an increase in drug8 plasma concentrations . "
              7 : "The concomitant use of other CYP3A4 inhibitors such as drug1 and drug2 with transdermal drug3 may also result in an increase in drug4 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression . "
              8 : "- drug1 , oral ( diabetes medicine you take by mouth ) Use of oral drug2 with drug3 may increase the chance of side effects affecting the blood and/or the side effects or oral drug4 "
              9 : "drug1 or other drug2 ( concurrent use with drug3 may result in uterine hypertonus , possibly causing uterine rupture or cervical laceration , especially in the absence of adequate cervical dilatation ; "
              10 : "The concomitant administration of drug1 including drug2 with drug3 ( a drug4 ) has , on rare occasions , resulted in severe hypoglycemia . "
            }
          5 : 
            {
              1 : "drug0 + ppmod drug0 +"
              2 : "drug0 + ppmod drug0 +"
              3 : "drug0 + ppmod drug0 +"
              4 : "drug0 + ppmod drug0 +"
              5 : "drug0 + ppmod drug0 +"
              6 : "drug0 + ppmod drug0 +"
              7 : "drug0 + ppmod drug0 +"
              8 : "drug0 + ppmod drug0 +"
              9 : "drug0 + ppmod drug0 +"
              10 : "drug0 + ppmod drug0 +"
            }
        }
    }
  11 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN ppmod NN"
          3 : 4
          4 : 
            {
              1 : "In this study , we found that the COMT drug1 SNP was significantly associated with a reduced risk of drug2 , especially drug3 , which suggests that this SNP may have a protective effect . "
              2 : "Moreover , the PLCH1 drug1 SNP was strongly associated with an increased risk of drug2 , "
              3 : "CONCLUSIONS : Donor TCF7L2 drug1 polymorphism is associated with an increased risk of drug2 after LT and has a potential clinical value for the prediction of NODM . "
              4 : "drug3 disease stage was marginally significantly associated with the frequency of the T variant at drug1 ( p=0.057 ; adjusted p=0.017 ) but not at drug2 ( p=0.5 ; adjusted p=0.2 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod risk ppmod drug0 + dep snp com drug0"
              2 : "associated + ppmod risk ppmod drug0 + dep snp com drug0"
              3 : "associated + ppmod risk ppmod drug0 + dep polymorphism com drug0"
              4 : "associated + dep stage com drug0 + ppmod frequency ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "drug1 treatment should be stopped during treatment with drug2 . "
            }
          5 : 
            {
              1 : "stopped + ppmod treatment ppmod drug0 + dep treatment com drug0"
            }
        }
    }
  12 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + conj NN"
          2 : "NN + conj NN + ppmod NN"
          3 : 4
          4 : 
            {
              1 : "CONCLUSIONS : The study extends on the observation of a strong multiethnic association of polymorphisms in the drug1 and drug2 with drug4 , but does not confirm the association of CPT1B/CHKB ( drug3 ) in the Chinese population . "
              2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "drug0 + ppmod drug0 + conj drug0"
              2 : "drug0 + ppmod drug0 + conj drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN + conj NN"
          2 : "NN + conj NN + ppmod NN"
          3 : 8
          4 : 
            {
              1 : "drug1 : Concomitant administration of drug2 containing drug3 or drug4 with drug5 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug6 components . "
              2 : "Oral drug1 : Coadministration of drug2 and an oral drug3 increased AUC values for drug4 and drug5 by approximately 30 % and 20 % . "
              3 : "The concomitant use of other CYP3A4 inhibitors such as drug1 and drug2 with transdermal drug3 may also result in an increase in drug4 plasma concentrations , which could increase or prolong adverse drug effects and may cause serious respiratory depression . "
              4 : "drug1 , Including Oral , Injectable , Transdermal , and Implantable drug2 : An interaction study demonstrated that co-administration of drug3 and the oral drug4 drug5 produced average decreases of drug6 and drug7 levels of 14 % and 31 % , respectively . "
              5 : "drug1 ( drug2 ) : Concomitant use of drug3 ( or other drug4 ) and drug5 increases the risk of gastrointestinal side effects . "
              6 : "drug1 / drug2 : An increase in the frequency of skin rash has been reported among patients receiving drug3 or drug4 concurrently with drug5 compared to patients who are not receiving both drugs . "
              7 : "The reddish color is due to the formation of a nonabsorbable complex between drug1 or its breakdown products and drug2 in the gastrointestinal tract . "
              8 : "Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using drug1 or drug2 concomitantly with drug3 . "
            }
          5 : 
            {
              1 : "drug0 + ppmod drug0 + conj drug0"
              2 : "coadministration + conj drug0 + ppmod drug0"
              3 : "drug0 + ppmod drug0 + conj drug0"
              4 : "co-administration + conj drug0 + ppmod drug0"
              5 : "use + conj drug0 + ppmod drug0"
              6 : "drug0 + ppmod drug0 + conj drug0"
              7 : "complex + conj drug0 + ppmod drug0"
              8 : "drug0 + ppmod drug0 + conj drug0"
            }
        }
    }
  13 : 
    {
      snpphena : 
        {
          1 : "VBN + dep NN + ppmod NN conj NN"
          2 : "VBN + ppmod NN conj NN + dep NN"
          3 : 4
          4 : 
            {
              1 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1.79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1.72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1.49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1.38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1.43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2.43 , p = 0.038 ) in TCF7L2 . "
            }
          5 : 
            {
              1 : "associated + dep drug0 + ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN conj NN + dep NN"
          2 : "VBN + dep NN + ppmod NN conj NN"
          3 : 27
          4 : 
            {
              1 : "drug1 should not be administered concomitantly with drug2 , drug3 , drug4 , drug5 , or drug6 . "
              2 : "Because of its primary CNS effect , caution should be used when drug1 is taken with other drug2 and drug3 . "
              3 : "Additive adverse effects resulting from cholinergic blockade may occur when drug1 is administered concomitantly with other drug2 , drug3 , drug4 , drug5 , drug6 , drug7 or some drug8 . "
              4 : "When drug1 was coadministered with drug2 , drug3 , or H2antagonists , reduced plasma concentrations of drug4 were reported . "
              5 : "Close supervision and careful adjustment of the dosage are required when drug1 is used with other drug2 or drug3 . "
              6 : "Caution should be observed when drug1 is coadministered with other drug2 , drug3 , drug4 , or drug5 , as these agents may increase respiratory and circulatory depression . "
              7 : "Close supervision and careful adjustment of dosage are required when drug1 is administered with drug2 or drug3 . "
              8 : "Additional reductions in blood pressure may occur when drug1 is administered with drug2 , drug3 , or other drug4 . "
              9 : "- drug1 or drug2 ( with hepatotoxic potential ) must not be administered together with drug3 or drug4 . "
              10 : "drug1 should not be taken closely in time with drug2 and drug3 containing drug4 . "
            }
          5 : 
            {
              1 : "administered + ppmod drug0 conj drug0 + dep drug0"
              2 : "taken + ppmod drug0 conj drug0 + dep drug0"
              3 : "administered + ppmod drug0 conj drug0 + dep drug0"
              4 : "coadministered + ppmod drug0 conj drug0 + dep drug0"
              5 : "used + ppmod drug0 conj drug0 + dep drug0"
              6 : "coadministered + ppmod drug0 conj drug0 + dep drug0"
              7 : "administered + ppmod drug0 conj drug0 + dep drug0"
              8 : "administered + ppmod drug0 conj drug0 + dep drug0"
              9 : "administered + ppmod drug0 conj drug0 + dep drug0"
              10 : "taken + ppmod drug0 conj drug0 + dep drug0"
            }
        }
    }
  14 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN"
          3 : 3
          4 : 
            {
              1 : "RESULTS : As previously reported in Spain , drug1 allele was strongly associated with drug2 in our series ( OR=2.88 [95 % C.I. 2.16- 3.84 ] , p=7.38E-11 ) . "
              2 : "Thus , the drug1 polymorphism is not associated with drug2 in the Caucasian population but acts as a modifier of the AAO in drug3 with a sexual dimorphism : the Val allele is associated with a younger AAO in men with idiopathic PD . "
              3 : "The OPRM1 drug1 genotype was associated with patients ' drug2 ratings at 15 min in the postanesthesia care unit ( PACU ) ( p = .01 ) and patients ' drug3 at 15 min in the PACU ( p = .02 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep allele com drug0"
              2 : "associated + ppmod drug0 + dep polymorphism com drug0"
              3 : "associated + ppmod drug0 + dep genotype com drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN"
          3 : 3
          4 : 
            {
              1 : "When drug1 dosing was separated from drug2 10 mg by 6 hours , 7 of 28 subjects who received 20 mg of drug3 experienced a decrease in standing systolic blood pressure below 85 mm Hg . "
              2 : "drug1 exposure was significantly decreased by drug2 ; "
              3 : "When drug1 HCl is administered concomitantly with an drug2 , the risk of hyperkalemia may be increased . "
            }
          5 : 
            {
              1 : "separated + ppmod drug0 + dep dosing com drug0"
              2 : "decreased + ppmod drug0 + dep exposure com drug0"
              3 : "administered + ppmod drug0 + dep hcl com drug0"
            }
        }
    }
  15 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN ppmod NN"
          3 : 3
          4 : 
            {
              1 : "Based on 12 studies with 5,573 MetS cases and 8,290 controls from 5 East Asian studies , 5 European studies and 2 studies of other ethnic groups , the drug1 was associated with increased risk of drug2 with an OR ( 95 % CI ) = 1.33 ( 1.16 , 1.53 ) in the overall population , 1.43 ( 1.29 , 1.58 ) in East Asian and 1.30 ( 0.94 , 1.78 ) in European populations . "
              2 : "In summary , by pooling all available qualified data from genetic studies on drug1 and drug3 , we have confirmed that drug2 is significantly associated with susceptibility to drug4 in the global population . "
              3 : "These data suggest that drug1 are associated with increased risk for drug2 in Emirati subjects . "
            }
          5 : 
            {
              1 : "associated + ppmod risk ppmod drug0 + dep drug0"
              2 : "associated + ppmod susceptibility ppmod drug0 + dep drug0"
              3 : "associated + ppmod risk ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN ppmod NN"
          3 : 18
          4 : 
            {
              1 : "Caution should be exercised when drug1 are given in conjunction with drug2 . "
              2 : "drug1 : The AUC of drug2 was increased about 4-fold when drug3 at 300 mg/day was coadministered with a single 200-mg dose of drug4 to two patients with renal impairment ( CLcr=15 and 18 mL/min ) . "
              3 : "If the two drugs are coadministered , the drug1 should be withdrawn several days before the gradual withdrawal of drug2 . "
              4 : "Consequently , it is recommended that drug1 not be used in combination with either drug2 , drug3 , or drug4 . "
              5 : "Concomitant administration of drug1 and drug2 is not recommended because drug3 is displaced from its binding sites during the concomitant administration of drug4 , resulting in lower plasma concentrations and peak plasma levels . "
              6 : "There are case reports of patients who developed increased BUN , serum creatinine and serum potassium levels , and weight gain when drug1 was used in conjunction with drug2 . "
              7 : "drug1 : Concomitant administration of drug2 and drug3 is not recommended because drug4 is displaced from its binding sites during the concomitant administration of drug5 , resulting in lower plasma concentrations , peak plasma levels , and AUC values . "
              8 : "Because of the possible additive effects of drugs that may depress the nervous system , drug1 or drug2 should be used cautiously in combination with drug3 . "
              9 : "Oral drug1 CAUTION SHOULD BE EXERCISED WHEN drug2 ARE GIVEN IN CONJUNCTION WITH drug3 . "
              10 : "drug1 should be used cautiously in conjunction with drug2 in hypoprothrombinemia . "
            }
          5 : 
            {
              1 : "given + ppmod conjunction ppmod drug0 + dep drug0"
              2 : "coadministered + ppmod dose ppmod drug0 + dep drug0"
              3 : "withdrawn + ppmod withdrawal ppmod drug0 + dep drug0"
              4 : "used + ppmod combination ppmod drug0 + dep drug0"
              5 : "displaced + ppmod administration ppmod drug0 + dep drug0"
              6 : "used + ppmod conjunction ppmod drug0 + dep drug0"
              7 : "displaced + ppmod administration ppmod drug0 + dep drug0"
              8 : "used + ppmod combination ppmod drug0 + dep drug0"
              9 : "given + ppmod conjunction ppmod drug0 + dep drug0"
              10 : "used + ppmod conjunction ppmod drug0 + dep drug0"
            }
        }
    }
  16 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN ppmod NN + dep NNS ppmod NN"
          2 : "VBN + dep NNS ppmod NN + ppmod NN ppmod NN"
          3 : 3
          4 : 
            {
              1 : "Our results strengthen the evidence that one or more variants in drug1 are associated with increased risk of drug2 . "
              2 : "Patients homozygous AA for TLR1 polymorphism drug1 are more frequently associated with faster decline of drug2 compared to heterozygous genotype ( OR:7.33 ( 95 % CI:1.63-33.11 ) "
              3 : "The minor alleles of drug1 ( TCF7L2 ) , drug2 ( TCF7L2 ) , drug3 ( -30G/A , GCK ) , drug4 ( E23K , KCNJ11 ) , drug5 ( CDKAL1 ) , drug6 ( IGF2BP2 ) , drug7 ( MTNR1B ) , drug8 ( MTNR1B ) and drug9 ( Gly972Arg , IRS1 ) were significantly associated with a higher risk of drug10 . "
            }
          5 : 
            {
              1 : "associated + ppmod risk ppmod drug0 + dep variants ppmod drug0"
              2 : "associated + ppmod decline ppmod drug0 + dep aa ppmod drug0"
              3 : "associated + ppmod risk ppmod drug0 + dep alleles ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + dep NNS ppmod NN + ppmod NN ppmod NN"
          2 : "VBN + ppmod NN ppmod NN + dep NNS ppmod NN"
          3 : 2
          4 : 
            {
              1 : "In the presence of these drug1 , larger doses of drug2 may be required or drug3 may not be effective . "
              2 : "The anxiogenic effects of drug1 were reduced by pretreatment with drug2 , an A2-selective agonist , but not by drug3 ( drug4 ) , an A1-selective agonist . "
            }
          5 : 
            {
              1 : "required + dep doses ppmod drug0 + ppmod presence ppmod drug0"
              2 : "reduced + ppmod pretreatment ppmod drug0 + dep effects ppmod drug0"
            }
        }
    }
  17 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN ppmod NN +"
          2 : "NN + + conj NN ppmod NN"
          3 : 3
          4 : 
            {
              1 : "The aim of this study was to assess the effect of drug1 , the intake of drug2 , and drug3 in Lithuanian adult population . "
              2 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
              3 : "We also found a strong correlation between the drug1 and the presence of drug2 ( P = 0.02 with a high OR = 8.28 ) . "
            }
          5 : 
            {
              1 : "drug0 + conj intake ppmod drug0 +"
              2 : "drug0 + conj drug0 ppmod drug0 +"
              3 : "drug0 + conj presence ppmod drug0 +"
            }
        }
      full : 
        {
          1 : "NN + conj NN ppmod NN +"
          2 : "NN + + conj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "After the coadministration of 200 mg oral drug1 twice daily and one 20 mg dose of drug2 to 11 subjects , the AUC and Cmax of drug3 averaged 302 % ( 142 S.D. ) and 251 % ( 68 S.D. ) , respectively , of those obtained after co-treatment with placebo . "
            }
          5 : 
            {
              1 : "drug0 + conj dose ppmod drug0 +"
            }
        }
    }
  18 : 
    {
      snpphena : 
        {
          1 : "NN + + conj NN com NN"
          2 : "NN + conj NN com NN +"
          3 : 3
          4 : 
            {
              1 : "The association between drug2 and SIRT2 drug1 T allele was only present in APOE e4 noncarriers ( adjusted OR = 1.29 , 95 % CI : 1.03-1.61 , P = .03 ) . "
              2 : "CONCLUSIONS : Although prefrontal cortical and ventral striatal activity are highly relevant for drug3 , and under partial control of drug1 genotype , no association between drug2 and drug4 behavior was observed "
              3 : "The association between drug1 and drug2 susceptibility has been widely studied . "
            }
          5 : 
            {
              1 : "drug0 + + conj allele com drug0"
              2 : "drug0 + conj behavior com drug0 +"
              3 : "drug0 + conj susceptibility com drug0 +"
            }
        }
      full : 
        {
          1 : "NN + conj NN com NN +"
          2 : "NN + + conj NN com NN"
          3 : 5
          4 : 
            {
              1 : "drug1 : When drug2 and drug3 suspension were coadministered , plasma concentrations of drug4 decreased approximately 35 % . "
              2 : "drug1 : Increased serum drug2 levels and symptoms of drug3 toxicity have been reported in patients receiving concomitant drug4 and drug5 therapy . "
              3 : "drug1 : Coadministration of drug2 and drug3 Suspension results in a significant decrease in average steady- state plasma drug4 concentrations . "
              4 : "There have been reports of drug1 -related side-effects in patients on concomitant drug2 - drug3 therapy . "
              5 : "Therapeutic drug monitoring can avoid iatrogenic alterations caused by drug1 ( MDP ) - drug2 interaction . "
            }
          5 : 
            {
              1 : "drug0 + conj suspension com drug0 +"
              2 : "drug0 + conj therapy com drug0 +"
              3 : "drug0 + conj suspension com drug0 +"
              4 : "drug0 + conj therapy com drug0 +"
              5 : "drug0 + conj interaction com drug0 +"
            }
        }
    }
  19 : 
    {
      snpphena : 
        {
          1 : "VBZ + obj NN ppmod NN + dep NN com NN"
          2 : "VBZ + dep NN com NN + obj NN ppmod NN"
          3 : 3
          4 : 
            {
              1 : "The drug1 allele of the COMT gene confers a significantly increased risk for drug2 and drug3 in drug4 . "
              2 : "CONCLUSIONS : The drug1 allele , associated with higher fasting triglyceride levels , strongly affects the risk for early-onset drug2 , even after adjusting for triglycerides . "
            }
          5 : 
            {
              1 : "confers + obj risk ppmod drug0 + dep allele com drug0"
              2 : "affects + obj risk ppmod drug0 + dep allele com drug0"
            }
        }
      full : 
        {
          1 : "VBZ + obj NN ppmod NN + dep NN com NN"
          2 : "VBZ + dep NN com NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "drug1 treatment , which causes a marked and persistent inhibition of cholinesterase activity , potentiates the effect of drug2 . "
            }
          5 : 
            {
              1 : "potentiates + obj effect ppmod drug0 + dep treatment com drug0"
            }
        }
    }
  20 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN + conj NN"
          2 : "NN + conj NN + conj NN"
          3 : 3
          4 : 
            {
              1 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous glucose tolerance tests were performed , and found an association between drug1 and drug2 and drug3 ( P = 0.003 and P = 0.005 , respectively ) and drug4 ( P = 0.04 and P = 0.007 , respectively ) . "
              2 : "We also genotyped these SNPs in nondiabetic , non-Amish subjects ( n = 48 ) , in whom intravenous drug3 tests were performed , and found an association between drug1 and drug2 and drug4 ( P = 0.003 and P = 0.005 , respectively ) and drug5 ( P = 0.04 and P = 0.007 , respectively ) . "
              3 : "No association was found for drug1 , drug2 , c.1,637C>A and drug3 ( p = 0.278-1.000 ) . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 + conj drug0"
              2 : "drug0 + conj drug0 + conj drug0"
              3 : "drug0 + conj drug0 + conj drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NN + conj NN"
          2 : "NN + conj NN + conj NN"
          3 : 3
          4 : 
            {
              1 : "The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 ( eg , drug2 ) , an drug3 ( eg , drug4 ) , and/or a drug5 ( eg , drug6 ) --commonly results in excessive anticholinergic effects , including dry mouth and associated dental complications , blurred vision , and , in patients exposed to high temperature and humidity , hyperpyrexia . "
              2 : "Due to a theoretical risk of a pharmacodynamic interaction , use of drug1 -containing or drug2 ( like drug3 or drug4 ) and drug5 within 24 hours of each other should be avoided ( see a href= frova_od.htm # CI CONTRAINDICATIONS ) . "
              3 : "drug1 - drug2 and the drug3 drug4 may have synergistic antidepressant activity if used concomitantly . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 + conj drug0"
              2 : "drug0 + conj drug0 + conj drug0"
              3 : "drug0 + conj drug0 + conj drug0"
            }
        }
    }
  21 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN ppmod NN conj NN"
          2 : "VBN + dep NN ppmod NN conj NN + ppmod NN"
          3 : 3
          4 : 
            {
              1 : "Inside this region of 16.3 kb , LD ( r2 = 0.14 ) between drug1 and drug2 was observed in drug3 , but not in drug4 and in controls . "
              2 : "CONCLUSIONS : The CC genotype and the recessive model of the variant drug1 ( IVS3C/T ) and CC haplotype of drug2 ( IVS3C/T ) and drug3 ( IVS3C/T ) in TCF7L2may be associated with drug4 in Han Chinese people in Henan province , China . . "
            }
          5 : 
            {
              1 : "observed + ppmod drug0 + dep ld ppmod drug0 conj drug0"
              2 : "associated + ppmod drug0 + dep genotype ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN ppmod NN conj NN"
          2 : "VBN + dep NN ppmod NN conj NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "Agents Causing Renin Release : The antihypertensive effect of drug1 and drug2 IV is augmented by drug3 that cause renin release ( e.g. , drug4 ) . "
              2 : "- The action of drug1 and drug2 may be enhanced by drug3 or drug4 . "
            }
          5 : 
            {
              1 : "augmented + ppmod drug0 + dep effect ppmod drug0 conj drug0"
              2 : "enhanced + ppmod drug0 + dep action ppmod drug0 conj drug0"
            }
        }
    }
  22 : 
    {
      snpphena : 
        {
          1 : "NNS + ppmod NN + appo NN conj NN"
          2 : "NNS + appo NN conj NN + ppmod NN"
          3 : 3
          4 : 
            {
              1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "snps + ppmod drug0 + appo drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "NNS + ppmod NN + appo NN conj NN"
          2 : "NNS + appo NN conj NN + ppmod NN"
          3 : 5
          4 : 
            {
              1 : "Patients receiving other drug1 s , general drug2 , drug3 , drug4 , drug5 , drug6 or other drug7 ( including drug8 ) concomitantly with drug9 may exhibit an additive CNS depression . "
            }
          5 : 
            {
              1 : "patients + ppmod drug0 + appo drug0 conj drug0"
            }
        }
    }
  23 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NNS attr NN"
          2 : "VBN + dep NNS attr NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "Though drug1 /C3/A4/A5 genetic polymorphisms are associated with drug2 , their effect on central drug3 is less known "
              2 : "We found that SNPs drug1 , drug2 , drug3 and drug4 in the TCF7L2 gene were strongly associated with drug5 ( p<0.004 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep polymorphisms attr drug0"
              2 : "associated + ppmod drug0 + dep snps attr drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NNS attr NN"
          2 : "VBN + dep NNS attr NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "It has been reported that results of studies in animals indicate that drug1 -induced ventricular arrhythmias during anesthesia can be reversed by drug2 . "
            }
          5 : 
            {
              1 : "reversed + ppmod drug0 + dep arrhythmias attr drug0"
            }
        }
    }
  24 : 
    {
      snpphena : 
        {
          1 : "VBP + obj NNS com NN + dep NN"
          2 : "VBP + dep NN + obj NNS com NN"
          3 : 2
          4 : 
            {
              1 : "Thus , we have shown that the drug1 and drug2 markers are independent genetic drug3 risk factors in a Russian population . "
            }
          5 : 
            {
              1 : "are + obj factors com drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBP + obj NNS com NN + dep NN"
          2 : "VBP + dep NN + obj NNS com NN"
          3 : 2
          4 : 
            {
              1 : "Since drug1 ( drug2 ) may interact with concurrently administered drug3 , periodic serum level determinations of these drugs may be necessary ( eg , drug4 may elevate drug5 serum levels and drug6 has been reported to both increase and decrease drug7 levels ) . "
              2 : "drug1 may elevate drug2 levels . "
            }
          5 : 
            {
              1 : "elevate + obj levels com drug0 + dep drug0"
              2 : "elevate + obj levels com drug0 + dep drug0"
            }
        }
    }
  25 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NNS attr NN"
          2 : "NN + ppmod NNS attr NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "For example , the association of polymorphisms drug1 and drug2 with drug3 was heterogeneous between Caucasians ( OR = 1.32 and 1.22 ; 95 % CI : 1.25-1.44 and 1.05-1.42 ; P<0.0005 and 0.008 , respectively ) and East Asians ( OR = 1.51 and 1.03 ; 95 % CI : 0.76-3 and 0.47-2.27 ; P = 0.237 and 0.934 , respectively ) under theallelic model , and this association was relatively strengthened under the dominant model . "
              2 : "We evaluated the published evidence for association between drug1 ( k = 27 samples ) and drug2 ( k = 44 samples ) SNPs with drug3 using meta-analytic techniques . "
            }
          5 : 
            {
              1 : "association + ppmod drug0 + ppmod polymorphisms attr drug0"
              2 : "association + ppmod drug0 + ppmod snps attr drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS attr NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NNS attr NN"
          3 : 2
          4 : 
            {
              1 : "The concomitant use of drug1 with drug2 and drug3 s may have additive effects on prolonging atrioventricular conduction time . "
              2 : "However , the antagonism of the drug1 -induced anxiogenic effects by drug2 was only observed in the time spent in the light zone , and drug3 -induced anxiogenic effects were neither reversed by drug4 nor by drug5 . "
            }
          5 : 
            {
              1 : "use + ppmod s attr drug0 + ppmod drug0"
              2 : "antagonism + ppmod drug0 + ppmod effects attr drug0"
            }
        }
    }
  26 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NNS attr NN conj NN"
          2 : "NN + ppmod NNS attr NN conj NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "For example , the association of polymorphisms drug1 and drug2 with drug3 was heterogeneous between Caucasians ( OR = 1.32 and 1.22 ; 95 % CI : 1.25-1.44 and 1.05-1.42 ; P<0.0005 and 0.008 , respectively ) and East Asians ( OR = 1.51 and 1.03 ; 95 % CI : 0.76-3 and 0.47-2.27 ; P = 0.237 and 0.934 , respectively ) under theallelic model , and this association was relatively strengthened under the dominant model . "
              2 : "We evaluated the published evidence for association between drug1 ( k = 27 samples ) and drug2 ( k = 44 samples ) SNPs with drug3 using meta-analytic techniques . "
            }
          5 : 
            {
              1 : "association + ppmod drug0 + ppmod polymorphisms attr drug0 conj drug0"
              2 : "association + ppmod drug0 + ppmod snps attr drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS attr NN conj NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NNS attr NN conj NN"
          3 : 1
          4 : 
            {
              1 : "The concomitant use of drug1 with drug2 and drug3 s may have additive effects on prolonging atrioventricular conduction time . "
            }
          5 : 
            {
              1 : "use + ppmod s attr drug0 conj drug0 + ppmod drug0"
            }
        }
    }
  27 : 
    {
      snpphena : 
        {
          1 : "NN + + ppmod NN conj NN"
          2 : "NN + ppmod NN conj NN +"
          3 : 2
          4 : 
            {
              1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "drug0 + + ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN conj NN +"
          2 : "NN + + ppmod NN conj NN"
          3 : 4
          4 : 
            {
              1 : "drug1 with drug2 or drug3 and possibly other drug4 cause striking and sustained increases in the concentration of drug5 in the brain ; "
              2 : "A study in eight healthy volunteers has shown a 50 % increase in mean peak drug1 plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of drug2 at 1,000 mg/day and drug3 at 90 mg/day . "
              3 : "drug1 Reversible increases in serum drug2 concentrations and toxicity have been reported during concomitant administration of drug3 with drug4 , and with some drug5 . "
            }
          5 : 
            {
              1 : "drug0 + ppmod drug0 conj drug0 +"
              2 : "drug0 + ppmod mg/day conj drug0 +"
              3 : "drug0 + ppmod drug0 conj drug0 +"
            }
        }
    }
  28 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN ppmod NN + conj NN"
          2 : "NN + conj NN + conj NN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 ppmod drug0 + conj drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NN + conj NN ppmod NN"
          2 : "NN + conj NN ppmod NN + conj NN"
          3 : 2
          4 : 
            {
              1 : "drug1 including drug2 , drug3 , and drug4 HC1 : Concomitant use of drug5 and non-selective drug6 may cause hypertension . "
              2 : "drug1 - Combined administration of racemic drug2 ( 40 mg ) and drug3 ( 200 mg ) decreased the Cmax and AUC of drug4 by 21 % and 10 % , respectively , and did not significantly affect the pharmacokinetics of drug5 . "
            }
          5 : 
            {
              1 : "drug0 + conj drug0 + conj use ppmod drug0"
              2 : "drug0 + conj drug0 + conj administration ppmod drug0"
            }
        }
    }
  29 : 
    {
      snpphena : 
        {
          1 : "NNS + conj NN + com NN"
          2 : "NNS + com NN + conj NN"
          3 : 2
          4 : 
            {
              1 : "There were no significant associations between drug1 genotypes and drug2 or drug3 . "
              2 : "There were no associations between drug1 polymorphisms and drug2 , drug3 and drug4 "
            }
          5 : 
            {
              1 : "genotypes + conj drug0 + com drug0"
              2 : "polymorphisms + conj drug0 + com drug0"
            }
        }
      full : 
        {
          1 : "NNS + conj NN + com NN"
          2 : "NNS + com NN + conj NN"
          3 : 1
          4 : 
            {
              1 : "drug1 : A relationship of functional antagonism exists between drug2 analogues , which promote calcium absorption , and drug3 , which inhibit calcium absorption . "
            }
          5 : 
            {
              1 : "analogues + conj drug0 + com drug0"
            }
        }
    }
  30 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NNS com NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NNS com NN"
          3 : 2
          4 : 
            {
              1 : "RESULTS : With multivariate generalized linear models , the association of TEF drug1 with drug2 symptoms was confirmed . "
              2 : "In association analysis , we found statistically significant association of drug1 ( p =0.001 , OR=3.011 , CI95 % =1.494-6.071 ) and drug2 ( p=2.62 * 10<formula>^ { -4 } </formula> , OR=14.117 , CI95 % = 1.884-105.799 ) polymorphisms with drug3 patients . "
            }
          5 : 
            {
              1 : "association + ppmod symptoms com drug0 + ppmod drug0"
              2 : "association + ppmod patients com drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS com NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NNS com NN"
          3 : 8
          4 : 
            {
              1 : "Coadministration of drug1 with 40 mg drug2 tablets in epileptic patients lowered the drug3 plasma concentrations to undetectable levels . "
              2 : "The use of drug1 or drug2 with drug3 preparations may increase the effect of either the drug4 or drug5 . "
              3 : "Coadministration of drug1 with drug2 tablets is therefore contraindicated . "
              4 : "Therefore concomitant administration of drug1 tablets with drug2 is contraindicated . "
              5 : "Coadministration of drug1 Tablets with drug2 or drug3 has resulted in elevated plasma concentrations of the latter two drugs . "
              6 : "Concomitant administration of drug1 tablets with drug2 may alter the metabolism of one or both of the drugs . "
              7 : "Concomitant administration of drug1 with drug2 tablets reduces the blood levels of the latter . "
              8 : "Concomitant administration of drug1 with drug2 capsules is not recommended . "
            }
          5 : 
            {
              1 : "coadministration + ppmod tablets com drug0 + ppmod drug0"
              2 : "use + ppmod preparations com drug0 + ppmod drug0"
              3 : "coadministration + ppmod tablets com drug0 + ppmod drug0"
              4 : "administration + ppmod drug0 + ppmod tablets com drug0"
              5 : "coadministration + ppmod drug0 + ppmod tablets com drug0"
              6 : "administration + ppmod drug0 + ppmod tablets com drug0"
              7 : "administration + ppmod tablets com drug0 + ppmod drug0"
              8 : "administration + ppmod capsules com drug0 + ppmod drug0"
            }
        }
    }
  31 : 
    {
      snpphena : 
        {
          1 : "VBN + dep NN + ppmod NN ppmod NN conj NN"
          2 : "VBN + ppmod NN ppmod NN conj NN + dep NN"
          3 : 2
          4 : 
            {
              1 : "Compared with controls ( men and women combined ) , drug10 was associated with drug1 and drug2 ( OR 1.55 , 95 % CI 1.34-1.79 , p = 4.17 x 10 ( -9 ) ) in CDKAL1 ; drug3 ( OR 1.49 , 95 % CI 1.29-1.72 , p = 1.05 x 10 ( -7 ) ) in the CDKN2A-CDKN2B region ; drug4 ( OR 1.27 , 95 % CI 1.09-1.49 , p = 0.003 ) , drug5 , and drug6 in HHEX ; drug7 ( OR 1.18 , 95 % CI 1.01-1.38 , p = 0.03 ) in IGF2BP2 ; drug8 ( OR 1.24 , 95 % CI 1.07-1.43 , p = 0.005 ) in SLC30A8 ; and drug9 ( OR 1.58 , 95 % CI 1.03-2.43 , p = 0.038 ) in TCF7L2 . "
            }
          5 : 
            {
              1 : "associated + dep drug0 + ppmod drug0 ppmod cdkal0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN ppmod NN conj NN + dep NN"
          2 : "VBN + dep NN + ppmod NN ppmod NN conj NN"
          3 : 3
          4 : 
            {
              1 : "Consequently , it is recommended that drug1 not be used in combination with either drug2 , drug3 , or drug4 . "
              2 : "Drug-Drug Interactions Given the primary CNS effects of drug1 , caution should be used when drug2 is taken in combination with other drug3 and drug4 . "
            }
          5 : 
            {
              1 : "used + ppmod combination ppmod drug0 conj drug0 + dep drug0"
              2 : "taken + ppmod combination ppmod drug0 conj drug0 + dep drug0"
            }
        }
    }
  32 : 
    {
      snpphena : 
        {
          1 : "NN + conj NN + com NN"
          2 : "NN + com NN + conj NN"
          3 : 2
          4 : 
            {
              1 : "RESULTS : In the discovery population , we observed an association between SIRT2 drug1 T allele and drug2 ( adjusted odds ratio [OR ] = 1.23 , 95 % confidence interval [CI ] : 1.02-1.50 , P = .02 , after correction for sex , age , and APOE e4 genotype ) . "
              2 : "However , no relationships were found between drug1 genotype and drug2 in 2 cohorts ( n=1648 and n=1039 ) of healthy middle-aged carriers of the APOE e3/e3 genotype . "
            }
          5 : 
            {
              1 : "allele + conj drug0 + com drug0"
              2 : "genotype + conj drug0 + com drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NN + com NN"
          2 : "NN + com NN + conj NN"
          3 : 4
          4 : 
            {
              1 : "Profound hypotensive episodes may occur when drug1 infection and drug2 are used concomitantly . "
              2 : "drug1 injection and drug2 should not be administered simultaneously because both drugs are direct cardiac stimulants and their combined effects may induce serious arrhythmias . "
              3 : "- In isolated cases , a pronounced though reversible , impairment of renal function ( accompanied by a corresponding increase in the serum creatinine level ) has been reported in organ transplant patients receiving drug1 therapy and concomitant drug2 . "
              4 : "Concomitant administration of drug1 Injection and drug2 in a wax matrix may increase the severity of potassium chloride-induced gastrointestinal lesions as a result of a slower gastrointestinal transit time . "
            }
          5 : 
            {
              1 : "infection + conj drug0 + com drug0"
              2 : "injection + conj drug0 + com drug0"
              3 : "therapy + conj drug0 + com drug0"
              4 : "injection + conj drug0 + com drug0"
            }
        }
    }
  33 : 
    {
      snpphena : 
        {
          1 : "NN + relcl VBN ppmod NN +"
          2 : "NN + + relcl VBN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "We evaluated the association of a polymorphism in TCF7L2 drug1 in the WNT signaling pathway , which previously has been strongly associated with risk of drug2 , with drug3 and drug4 in the prospective Nurses ' Health Study ( NHS ) and Health ProfessionalsFollow-up Study ( HPFS ) cohorts . "
              2 : "Specifically , the same risk allele of single nucleotide polymorphism ( SNP ) drug1 that is associated with drug2 ( T allele ) has recently been associated with an increased risk of drug3 . "
            }
          5 : 
            {
              1 : "drug0 + relcl associated ppmod drug0 +"
              2 : "drug0 + relcl associated ppmod drug0 +"
            }
        }
      full : 
        {
          1 : "NN + relcl VBN ppmod NN +"
          2 : "NN + + relcl VBN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Clinically significant effects have been reported with the drug1 when used concomitantly with drug2 . "
            }
          5 : 
            {
              1 : "drug0 + relcl used ppmod drug0 +"
            }
        }
    }
  34 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN attr NN"
          2 : "VBN + dep NN attr NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The drug1 ( T ) allele genotype was significantly associated with drug3 ( P = 0.003 ) but drug2 ( T ) allele genotype was not associated with the clinico-pathologic characteristics . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep genotype attr drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN attr NN"
          2 : "VBN + dep NN attr NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "drug1 steady-state Cmax , A.C. and Cmin were decreased by 22 % , 38 % , and 27 % , respectively , by concomitant drug2 . "
              2 : "drug1 steady-state Cmax , A.C. and Cmin were increased by 12 % , 15 % , and 14 % , respectively , by concomitant drug2 . "
            }
          5 : 
            {
              1 : "decreased + ppmod drug0 + dep cmax attr drug0"
              2 : "increased + ppmod drug0 + dep cmax attr drug0"
            }
        }
    }
  35 : 
    {
      snpphena : 
        {
          1 : "VBN + comp VB obj NN ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + comp VB obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The minor T allele of TCF7L2 drug1 was found to significantly increase the risk of drug2 , with an allelic odds ratio ( OR ) of 1.458 ( 95 % CI 1.108-1.918 , p = 0.007 ) . "
            }
          5 : 
            {
              1 : "found + comp increase obj risk ppmod drug0 + dep allele ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + comp VB obj NN ppmod NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + comp VB obj NN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "The concomitant administration of drug1 has been reported to reduce the efficacy of oral drug2 and to increase the incidence of breakthrough bleeding . "
              2 : "Prior administration of drug1 ( 90 mg kg ( -1 ) body weight ) was shown to prevent the conversion of drug2 ( 100 mg kg ( -1 ) body weight ) to drug3 in vivo and to eliminate the fluoride and citrate elevations seen in drug4 -intoxicated animals . "
            }
          5 : 
            {
              1 : "reported + comp reduce obj efficacy ppmod drug0 + dep administration ppmod drug0"
              2 : "shown + comp prevent obj conversion ppmod drug0 + dep administration ppmod drug0"
            }
        }
    }
  36 : 
    {
      snpphena : 
        {
          1 : "VBD + obj NN com NN + dep NN ppmod NN"
          2 : "VBD + dep NN ppmod NN + obj NN com NN"
          3 : 1
          4 : 
            {
              1 : "Among women with a history of drug2 , the TT genotype of drug1 increased drug3 risk ( OR , 2.46 ; 95 % CI 1.28-4.73 ) "
            }
          5 : 
            {
              1 : "increased + obj risk com drug0 + dep genotype ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBD + obj NN com NN + dep NN ppmod NN"
          2 : "VBD + dep NN ppmod NN + obj NN com NN"
          3 : 6
          4 : 
            {
              1 : "however , 150 mg of drug1 q12h for 3 days increased the drug2 C max by 23 % and drug3 AUC by 16 % . "
              2 : "Multiple-dose administration of the potent CYP3A4 inducer drug1 ( 600 mg every 24 hours , q24h , for 14 days ) , however , reduced drug2 Cmax and AUC by approximately 80 % . "
              3 : "Pre-treatment with the CYP3A4 inducer drug1 decreased drug2 AUC by about 2/3 . "
              4 : "however , in a study of 12 normal subjects , concurrent administration of drug1 decreased drug2 protein binding and increased drug3 plasma clearance from 0.07 L/kg/h without drug4 to 0.11 L/kg/h with drug5 . "
              5 : "Co-administration of drug1 reduced drug2 Cmax up to 50 % after multiple dosing . "
              6 : "Withdrawal of drug1 decreased the drug2 requirement by 50 % . "
            }
          5 : 
            {
              1 : "increased + obj max com drug0 + dep mg ppmod drug0"
              2 : "reduced + obj cmax com drug0 + dep administration ppmod drug0"
              3 : "decreased + obj auc com drug0 + dep pre-treatment ppmod drug0"
              4 : "decreased + obj binding com drug0 + dep administration ppmod drug0"
              5 : "reduced + obj cmax com drug0 + dep co-administration ppmod drug0"
              6 : "decreased + obj requirement com drug0 + dep withdrawal ppmod drug0"
            }
        }
    }
  37 : 
    {
      snpphena : 
        {
          1 : "NNS + conj NNS + com NN"
          2 : "NNS + com NN + conj NNS"
          3 : 1
          4 : 
            {
              1 : "Meta-analysis indicated compelling evidence of an association between the drug1 variants and drug2 ( fixed effects : B = 0.91 , 95 % CI = 0.77 , 1.06 , p < .001 ; random effects : B = 1.01 , 95 % CI = 0.81 , 1.22 , p < .001 ) , equivalent to a per-allele effect of approximately 1 cigarette/day . "
            }
          5 : 
            {
              1 : "variants + conj drug0 + com drug0"
            }
        }
      full : 
        {
          1 : "NNS + conj NNS + com NN"
          2 : "NNS + com NN + conj NNS"
          3 : 4
          4 : 
            {
              1 : "drug1 : The co-administration of drug2 Tablets and drug3 is generally not advisable . "
              2 : "The concomitant use of drug1 s , vasoconstricting agents ( such as drug2 ) and some drug3 may result in severe hypertension . "
              3 : "Concomitant use of drug1 supplements and drug2 may increase drug3 absorption "
              4 : "Concomitant administration of drug1 capsules and drug2 resulted in substantial increases in plasma concentrations of drug3 , probably at least partially related to cytochrome P450 3A4 inhibition by drug4 . "
            }
          5 : 
            {
              1 : "tablets + conj drug0 + com drug0"
              2 : "s + conj drug0 + com drug0"
              3 : "supplements + conj drug0 + com drug0"
              4 : "capsules + conj drug0 + com drug0"
            }
        }
    }
  38 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN com NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "The drug1 variant was not significantly associated with drug2 status or snus use ( P > 0.05 ) ; the T allele was associated with lower BMI in the overall cohort ( b = -0.10 kg/m ( 2 ) , SE = 0.05 ; P = 0.03 ) and with drug3 quantity in those in whom this was measured ( n = 5,304 ) ( b = 0.08 , SE = 0.01 ; P < 0.0001 ) "
            }
          5 : 
            {
              1 : "associated + ppmod status com drug0 + dep variant com drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN com NN + dep NN com NN"
          2 : "VBN + dep NN com NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "drug1 : A literature article reported that when a 60-mg controlled-release drug2 capsule was administered 2 hours prior to a 600-mg drug3 capsule ( N=12 ) , mean drug4 AUC increased by 44 % compared to drug5 administered without drug6 . "
            }
          5 : 
            {
              1 : "administered + ppmod capsule com drug0 + dep capsule com drug0"
            }
        }
    }
  39 : 
    {
      snpphena : 
        {
          1 : "VBN + dep NN ppmod NN + ppmod NNS appo NN"
          2 : "VBN + ppmod NNS appo NN + dep NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "In addition , an association of two SNPs of the TCF7L2 gene with drug3 was observed in both cities : drug1 , ( for Guerrero OR = 1.98 CI95 % 1.02-3.89 and for Mexico OR = 1.94 CI95 % 1.31-2.88 ) and drug2 ( OR = 1.79 CI95 % 1.08-2.97 , OR = 1.78 CI95 % 1.17-2.71 respectively ) . "
            }
          5 : 
            {
              1 : "observed + dep association ppmod drug0 + ppmod cities appo drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NNS appo NN + dep NN ppmod NN"
          2 : "VBN + dep NN ppmod NN + ppmod NNS appo NN"
          3 : 1
          4 : 
            {
              1 : "Although no clinical studies have been conducted , it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers ( such as drug2 , drug3 , drug4 ) , CYP3A4 inhibitors ( azole antimycotics e.g. , drug5 ; "
            }
          5 : 
            {
              1 : "affected + ppmod inducers appo drug0 + dep metabolism ppmod drug0"
            }
        }
    }
  40 : 
    {
      snpphena : 
        {
          1 : "VBD + obj NN ppmod NN + dep NN com NN"
          2 : "VBD + dep NN com NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The TCF7L2 drug1 polymorphism showed the highest odds ratio ( OR ) for drug2 ( OR 1.714 [1.298-2.263 ] ) . "
            }
          5 : 
            {
              1 : "showed + obj ratio ppmod drug0 + dep polymorphism com drug0"
            }
        }
      full : 
        {
          1 : "VBD + obj NN ppmod NN + dep NN com NN"
          2 : "VBD + dep NN com NN + obj NN ppmod NN"
          3 : 3
          4 : 
            {
              1 : "drug1 : drug2 IV/IM reduced the drug3 response to drug4 in normovolemic healthy subjects by approximately 20 % ( mean sodium and urinary output decreased 17 % ) . "
              2 : "drug1 : In a study of 7 healthy male volunteers , drug2 treatment potentiated the blood glucose lowering effect of drug3 ( a drug4 similar to drug5 ) in 3 of the 7 subjects . "
              3 : "drug1 pretreatment augmented the depressant effect of drug2 on the early components P1 and N1 , while attenuating drug3 's influence on components P2 and P3 . "
            }
          5 : 
            {
              1 : "reduced + obj response ppmod drug0 + dep iv/im com drug0"
              2 : "potentiated + obj effect ppmod drug0 + dep treatment com drug0"
              3 : "augmented + obj effect ppmod drug0 + dep pretreatment com drug0"
            }
        }
    }
  41 : 
    {
      snpphena : 
        {
          1 : "VBZ + obj NN com NN + dep NN ppmod NN"
          2 : "VBZ + dep NN ppmod NN + obj NN com NN"
          3 : 1
          4 : 
            {
              1 : "Our data suggest that the haplotype restricted to Europe is the strongest marker for drug2 globally and add further inferential evidence that the derived allele of drug1 is an East Asian drug3 allele . "
            }
          5 : 
            {
              1 : "is + obj allele com drug0 + dep allele ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBZ + obj NN com NN + dep NN ppmod NN"
          2 : "VBZ + dep NN ppmod NN + obj NN com NN"
          3 : 2
          4 : 
            {
              1 : "Concomitant use of drug1 usually depresses drug2 activity and may necessitate raising the dosage . "
              2 : "Co-treatment with the potent CYP3A4 inhibitor drug1 increases drug2 AUC by 2/3 . "
            }
          5 : 
            {
              1 : "depresses + obj activity com drug0 + dep use ppmod drug0"
              2 : "increases + obj auc com drug0 + dep co-treatment ppmod drug0"
            }
        }
    }
  42 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + advcl VBN ppmod NNS ppmod NN"
          2 : "VBN + advcl VBN ppmod NNS ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Significant evidence for association was observed for high TG for the T alleles of drug1 and drug2 ( p = 0.005 and p = 0.01 ) in Mexican drug3 families , No evidence for association was observed for drug4 , drug5 , drug6 in Mexicans . "
            }
          5 : 
            {
              1 : "observed + ppmod drug0 + advcl observed ppmod alleles ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + advcl VBN ppmod NNS ppmod NN"
          2 : "VBN + advcl VBN ppmod NNS ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Although acid-base and electrolyte disturbances were not reported in the clinical trials with drug1 , these disturbances have been reported with oral drug2 and have , in some instances , resulted in drug interactions ( e.g. , toxicity associated with high-dose drug3 therapy ) . "
            }
          5 : 
            {
              1 : "reported + ppmod drug0 + advcl reported ppmod trials ppmod drug0"
            }
        }
    }
  43 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN conj NN"
          2 : "VBN + dep NN conj NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "These data show that drug1 and drug2 are significantly associated with high drug3 in drug4 families from two different populations . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN conj NN"
          2 : "VBN + dep NN conj NN + ppmod NN"
          3 : 5
          4 : 
            {
              1 : "Because both of these drugs have negative inotropic properties and the effects of coadministration with drug1 are unknown , neither drug2 nor drug3 should be administered concurrently with drug4 unless , in the judgment of the physician , the benefits of this combination outweigh the risks . "
              2 : "- When drug1 or drug2 is used concurrently with drug3 ( e.g. drug4 ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of drug5 or drug6 is impaired "
              3 : "- drug1 or drug2 ( with hepatotoxic potential ) must not be administered together with drug3 or drug4 . "
              4 : "However , because bleeding has been reported when drug1 and other drug2 have been administered to patients on drug3 , the physician should be cautious when administering drug4 to patients on drug5 . "
              5 : "Prolonged recovery time may occur if drug1 and/or drug2 are used concurrently with drug3 . "
            }
          5 : 
            {
              1 : "administered + ppmod drug0 + dep drug0 conj drug0"
              2 : "used + ppmod drug0 + dep drug0 conj drug0"
              3 : "administered + ppmod drug0 + dep drug0 conj drug0"
              4 : "administered + ppmod drug0 + dep drug0 conj drug0"
              5 : "used + ppmod drug0 + dep drug0 conj drug0"
            }
        }
    }
  44 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NN appo NN"
          2 : "VBN + dep NN appo NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "One representative variant , drug1 , was nominally associated with drug2 in a general model ( additive P = 0.03 , dominant P = 0.005 ) but not in a within-family analysis ( additive P = 0.2 , dominant P = 0.07 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep variant appo drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NN appo NN"
          2 : "VBN + dep NN appo NN + ppmod NN"
          3 : 2
          4 : 
            {
              1 : "drug1 : drug2 can be used with low dose drug3 . "
              2 : "drug1 : drug2 are inhibited by drug3 . "
            }
          5 : 
            {
              1 : "used + ppmod drug0 + dep drug0 appo drug0"
              2 : "inhibited + ppmod drug0 + dep drug0 appo drug0"
            }
        }
    }
  45 : 
    {
      snpphena : 
        {
          1 : "VBD + obj NN ppmod NN + dep NN"
          2 : "VBD + dep NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "For the combined sample set , in which we successfully genotyped 1,174 type 2 diabetes patients and 823 control subjects , drug1 showed a significant association with drug2 ( odds ratio = 1.69 [95 % CI 1.21-2.36 ] , p = 0.002 ) with the same direction as the previous reports in samples from European and European-origin populations . "
            }
          5 : 
            {
              1 : "showed + obj association ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBD + obj NN ppmod NN + dep NN"
          2 : "VBD + dep NN + obj NN ppmod NN"
          3 : 27
          4 : 
            {
              1 : "drug1 decreased the hyperuricemic effect of drug2 . "
              2 : "drug1 significantly prolonged the half-life of drug2 to 26 hours . "
              3 : "drug1 reduced the blood AUC0-12 of drug2 by approximately 20 % , peak blood concentration ( Cmax ) by 16 % , and 12-hour blood concentration ( C12hr ) by 26 % in healthy subjects when drug3 ( 2 doses of 0.1 mg/kg 12 hours apart ) was administered on the 10th day of drug4 70 mg daily , as compared to results from a control period in which drug5 was administered alone . "
              4 : "In two clinical studies , drug1 ( one 4 mg/kg dose or two 3 mg/kg doses ) increased the AUC of drug2 by approximately 35 % . "
              5 : "Pharmacokinetic studies have demonstrated that drug1 and drug2 significantly increased the systemic exposure of drug3 and/or its major metabolites . "
              6 : "drug1 , when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3 , increased the AUC of drug2 , a CYP3A4 substrate , by 1.34-fold on Day 1 and by 2.5-fold on Day 3 , when drug3 was coadministered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3 . "
              7 : "drug1 : drug2 increased the AUC of drug3 , a sensitive CYP3A4 substrate , by 2.3-fold on Day 1 and 3.3-fold on Day 5 , when a single oral dose of drug4 2 mg was coadministered on Day 1 and Day 5 of a regimen of drug5 125 mg on Day 1 and 80 mg/day on Days 2 through 5 . "
              8 : "drug1 increased the AUC of drug2 by 25 % on Day 4 and decreased the AUC of drug3 by 19 % on Day 8 relative to the dosing of drug4 on Days 1 through 3 . "
              9 : "drug1 increased the AUC of drug2 by 50 % . "
              10 : "drug1 : In a study of healthy volunteers , drug2 significantly reduced the bioavailability of drug3 . "
            }
          5 : 
            {
              1 : "decreased + obj effect ppmod drug0 + dep drug0"
              2 : "prolonged + obj half-life ppmod drug0 + dep drug0"
              3 : "reduced + obj blood ppmod drug0 + dep drug0"
              4 : "increased + obj auc ppmod drug0 + dep drug0"
              5 : "increased + obj exposure ppmod drug0 + dep drug0"
              6 : "increased + obj auc ppmod drug0 + dep drug0"
              7 : "increased + obj auc ppmod drug0 + dep drug0"
              8 : "increased + obj auc ppmod drug0 + dep drug0"
              9 : "increased + obj auc ppmod drug0 + dep drug0"
              10 : "reduced + obj bioavailability ppmod drug0 + dep drug0"
            }
        }
    }
  46 : 
    {
      snpphena : 
        {
          1 : "VBD + ppmod NN com NN + dep NN com NN"
          2 : "VBD + dep NN com NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "In conclusion , this study indicated that the drug1 polymorphism of the TCF7L2 gene had a significant effect on drug4 risk in Chinese Han population , with drug2 and drug3 polymorphisms showing no significant effect . "
            }
          5 : 
            {
              1 : "had + ppmod risk com drug0 + dep polymorphism com drug0"
            }
        }
      full : 
        {
          1 : "VBD + ppmod NN com NN + dep NN com NN"
          2 : "VBD + dep NN com NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "This report describes two cases in which drug1 clearance accelerated markedly with concomitant drug2 administration . "
            }
          5 : 
            {
              1 : "accelerated + ppmod administration com drug0 + dep clearance com drug0"
            }
        }
    }
  47 : 
    {
      snpphena : 
        {
          1 : "VBZ + obj NN ppmod NN + dep NN"
          2 : "VBZ + dep NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Our findings suggest that drug1 in CHRNA is a susceptibility variant for drug2 , in terms of both airway obstruction and parenchyma destruction . "
            }
          5 : 
            {
              1 : "is + obj variant ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBZ + obj NN ppmod NN + dep NN"
          2 : "VBZ + dep NN + obj NN ppmod NN"
          3 : 26
          4 : 
            {
              1 : "drug1 reduces the clearance of drug2 . "
              2 : "Drug Interactions : drug1 may interact with some drugs , like drug2 ( drug3 ) : drug4 could theoretically affect drug5 pharmacodynamics - drug6 - Eproxindine - drug7 : drug8 and drug9 cause additive CNS depression - drug10 : drug11 increases the effect of drug12 "
              3 : "drug1 increases the clearance of drug2 by 15 % or more , possibly due to the induction of glutathione-S-transferase . "
              4 : "Because drug1 reduces the clearance of both drug2 and its active metabolite , drug3 , there is a strong likelihood of substantial accumulation of both species during chronic co-administration . "
              5 : "Drugs that may have their plasma concentration altered by drug1 drug2 increases the mean cmax and AUC of drug3 ( CYP3A4 substrate ) 2- and 3.5-fold , respectively , suggesting an inhibition of the CYP3A4 by drug4 . "
              6 : "Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug2 resulting in an eight-fold increase in the mean AUC of drug3 . "
              7 : "drug1 : In vitro data indicate that drug2 inhibits the metabolism of drug3 , which can result in an increase in plasma drug4 levels and prolongation of the QT interval on the ECG . "
              8 : "Human pharmacokinetic data indicate that oral drug1 markedly inhibits the metabolism of drug2 , resulting in a mean eight-fold increase in AUC of drug3 . "
              9 : "Oral drug1 inhibits the gastrointestinal absorption of drug2 , oral drug3 , drug4 and drug5 . "
              10 : "Animal experience indicates that drug1 prolongs the sleeping time after drug2 or after drug3 , increases the inhibitory effects of drug4 , but does not exhibit monoamine oxidase inhibition . "
            }
          5 : 
            {
              1 : "reduces + obj clearance ppmod drug0 + dep drug0"
              2 : "increases + obj effect ppmod drug0 + dep drug0"
              3 : "increases + obj clearance ppmod drug0 + dep drug0"
              4 : "reduces + obj clearance ppmod drug0 + dep drug0"
              5 : "increases + obj cmax ppmod drug0 + dep drug0"
              6 : "inhibits + obj metabolism ppmod drug0 + dep drug0"
              7 : "inhibits + obj metabolism ppmod drug0 + dep drug0"
              8 : "inhibits + obj metabolism ppmod drug0 + dep drug0"
              9 : "inhibits + obj absorption ppmod drug0 + dep drug0"
              10 : "prolongs + obj time ppmod drug0 + dep drug0"
            }
        }
    }
  48 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN com NN + dep NN"
          2 : "VBN + dep NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "Three SNPs[ drug1 in APOE : odds ratio ( OR ) =4.24 , 95 % confidence interval ( CI ) =3.01-5.96 , P=1.23 * 10 ; drug2 in APOE : OR=3.57 , 95 % CI=2.51-5.06 , P=1.23 * 10 ; and drug3 in PICALM : OR=0.63 , 95 % CI=0.49-0.81 , P=0.00036 , log additive model ] were significantly associated with drug4 susceptibility after correction for multiple testing . "
            }
          5 : 
            {
              1 : "associated + ppmod susceptibility com drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN com NN + dep NN"
          2 : "VBN + dep NN + ppmod NN com NN"
          3 : 6
          4 : 
            {
              1 : "drug1 , drug2 and drug3 should not be administered during drug4 treatment . "
              2 : "When drug1 is added to drug2 therapy , plasma drug3 levels may increase two-fold or more in some patients , if drug4 dosage is not reduced . "
              3 : "There have been isolated reports of patients experiencing increases in their prothrombin times when drug1 was added to drug2 therapy . "
              4 : "It is recommended that drug1 be taken at least 2 hours following drug2 administration . "
              5 : "When drug1 is added to drug2 therapy , drug3 dose should be doubled . "
              6 : "Median gastric pH was significantly higher when drug1 was taken after drug2 administration ; "
            }
          5 : 
            {
              1 : "administered + ppmod treatment com drug0 + dep drug0"
              2 : "added + ppmod therapy com drug0 + dep drug0"
              3 : "added + ppmod therapy com drug0 + dep drug0"
              4 : "taken + ppmod administration com drug0 + dep drug0"
              5 : "added + ppmod therapy com drug0 + dep drug0"
              6 : "taken + ppmod administration com drug0 + dep drug0"
            }
        }
    }
  49 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NNS ppmod NN prn NN"
          2 : "VBN + dep NNS ppmod NN prn NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The risk alleles of the TCF7L2 gene ( drug1 and drug2 ) were strongly associated with drug3 , even after controlling for traditional risk factors in both a cross-sectional and prospective setting . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep alleles ppmod gene prn drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NNS ppmod NN prn NN"
          2 : "VBN + dep NNS ppmod NN prn NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Inhibitors of this isoenzyme ( e.g. , drug1 , drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , grapefruit juice , drug8 , drug9 , drug10 , drug11 ) should be cautiously coadministered with drug12 as they can potentially increase drug13 levels . "
            }
          5 : 
            {
              1 : "coadministered + ppmod drug0 + dep inhibitors ppmod isoenzyme prn drug0"
            }
        }
    }
  50 : 
    {
      snpphena : 
        {
          1 : "NN + + prn NN com NN"
          2 : "NN + prn NN com NN +"
          3 : 1
          4 : 
            {
              1 : "The distributions of SNPs relating to the amyloid cascade hypothesis ( TOMM40 drug1 G and TOMM40 drug2 G ) , to the drug8 ( ApoE drug3 C , LDLR drug4 G and CH25H drug5 T and PLAU drug6 CT ) and to the tau hypothesis ( MAPT/STH drug7 GG ) in aMCI were significantly different than those in normal controls . "
            }
          5 : 
            {
              1 : "drug0 + + prn c com drug0"
            }
        }
      full : 
        {
          1 : "NN + prn NN com NN +"
          2 : "NN + + prn NN com NN"
          3 : 1
          4 : 
            {
              1 : "drug1 , drug2 , drug3 ( consider drug4 dose reduction ) . "
            }
          5 : 
            {
              1 : "drug0 + prn reduction com drug0 +"
            }
        }
    }
  51 : 
    {
      snpphena : 
        {
          1 : "VBD + dep NN + obj NN ppmod NN com NN"
          2 : "VBD + obj NN ppmod NN com NN + dep NN"
          3 : 1
          4 : 
            {
              1 : "RESULTS : drug2 compared to healthy individuals demonstrated a statistically significant increase in drug1 allele ( p = 0.037 , OR = 2.12 , 95 % CI 1.29-3.4 ) . "
            }
          5 : 
            {
              1 : "demonstrated + dep drug0 + obj increase ppmod allele com drug0"
            }
        }
      full : 
        {
          1 : "VBD + obj NN ppmod NN com NN + dep NN"
          2 : "VBD + dep NN + obj NN ppmod NN com NN"
          3 : 3
          4 : 
            {
              1 : "drug1 ( 500 mg t.i.d ) produced a 4-fold increase in drug2 AUC and a 3-fold increase in Cmax when co-administered with drug3 5 mg in healthy volunteers . "
              2 : "drug1 ( 200 mg once daily ) produced a 10-fold increase in drug2 AUC and a 4-fold increase in Cmax when co-administered with drug3 ( 5 mg ) in healthy volunteers . "
              3 : "drug1 : drug2 caused a decrease in drug3 phosphorylation ( 50 % inhibition of total phosphate formation ) in U937/Molt 4 cells . "
            }
          5 : 
            {
              1 : "produced + obj increase ppmod auc com drug0 + dep drug0"
              2 : "produced + obj increase ppmod auc com drug0 + dep drug0"
              3 : "caused + obj decrease ppmod phosphorylation com drug0 + dep drug0"
            }
        }
    }
  52 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NNS appo NN"
          2 : "NN + ppmod NNS appo NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "We investigated the effect of single nucleotide polymorphisms ( SNP ) , drug1 and drug2 , within the TCF7L2 locus on drug3 and other drug4 and their modulation by dietary fat . "
            }
          5 : 
            {
              1 : "effect + ppmod drug0 + ppmod polymorphisms appo drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS appo NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NNS appo NN"
          3 : 1
          4 : 
            {
              1 : "Multivalent Cation-Containing Products : Concurrent administration of a drug1 , including drug2 , with multivalent cation-containing products such as drug3 or drug4 drug5 , drug6 , drug7 chewable/buffered tablets or pediatric powder , or products containing drug8 , drug9 , or drug10 may substantially decrease the absorption of drug11 , resulting in serum and urine levels considerably lower than desired . "
            }
          5 : 
            {
              1 : "administration + ppmod products appo drug0 + ppmod drug0"
            }
        }
    }
  53 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + acl VBN ppmod NN"
          2 : "NN + acl VBN ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Carbohydrate quality and quantity modified risk of drug2 associated with drug1 , which suggests that changes in risk attributable to the TCF7L2 variant are magnified under conditions of increased insulin demand . "
            }
          5 : 
            {
              1 : "risk + ppmod drug0 + acl associated ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + acl VBN ppmod NN + ppmod NN"
          2 : "NN + ppmod NN + acl VBN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Although a 3-day regimen of drug1 given concomitantly with oral drug2 has not been studied , alternative or back-up methods of contraception should be used . "
            }
          5 : 
            {
              1 : "regimen + acl given ppmod drug0 + ppmod drug0"
            }
        }
    }
  54 : 
    {
      snpphena : 
        {
          1 : "VBN + dep NN + ppmod NNS ppmod NN"
          2 : "VBN + ppmod NNS ppmod NN + dep NN"
          3 : 1
          4 : 
            {
              1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [1.13-4.51 ] ) and 6q21 drug2 ( OR = 1.60 [1.10-2.34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [0.11-0.74 ] ) and DEFB1 drug4 ( OR = 0.50 [0.30-0.80 ] ) . "
            }
          5 : 
            {
              1 : "associated + dep drug0 + ppmod alleles ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NNS ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NNS ppmod NN"
          3 : 11
          4 : 
            {
              1 : "Caution should be exercised if an drug1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drug2 , drug3 , and drug4 . "
              2 : "drug1 should not be administered concurrently with D2-antagonists , such as drug2 , drug3 , drug4 , or drug5 . "
              3 : "Therefore , drug1 should be taken at least 1 hour before or 4-6 hours after a drug2 to avoid impeding its absorption . "
              4 : "Additive CNS depression may occur when drug1 are administered concomitantly with other drug2 including drug3 , drug4 , and drug5 . "
              5 : "therefore , drug1 should be administered ( with food ) one hour after or more than two hours before drug2 . "
              6 : "drug1 should not be taken within 2 hours of drug2 . "
              7 : "When drug1 is co-administered with inducers of drug clearance , such as drug2 , drug3 , drug4 , drug5 , or drug6 , use of a daily dose of 70 mg of drug7 should be considered "
              8 : "Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes , caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug3 and drug4 or inhibitors of CYP2C19 such as drug5 . "
              9 : "drug1 should not be administered concomitantly with potent drug2 such as drug3 and drug4 as the potential for ototoxicity is enhanced by the combination . "
              10 : "Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window , such as drug2 , drug3 and drug4 ( see CLINICAL PHARMACOLOGY ) . "
            }
          5 : 
            {
              1 : "administered + ppmod drugs ppmod drug0 + dep drug0"
              2 : "administered + ppmod d0-antagonists ppmod drug0 + dep drug0"
              3 : "taken + ppmod hours ppmod drug0 + dep drug0"
              4 : "administered + ppmod drug0 ppmod drug0 + dep drug0"
              5 : "administered + ppmod hours ppmod drug0 + dep drug0"
              6 : "taken + ppmod hours ppmod drug0 + dep drug0"
              7 : "co-administered + ppmod inducers ppmod drug0 + dep drug0"
              8 : "coadministered + ppmod inhibitors ppmod drug0 + dep drug0"
              9 : "administered + ppmod drug0 ppmod drug0 + dep drug0"
              10 : "used + ppmod medications ppmod drug0 + dep drug0"
            }
        }
    }
  55 : 
    {
      snpphena : 
        {
          1 : "VBN + dep NN + ppmod NNS ppmod NN conj NN"
          2 : "VBN + ppmod NNS ppmod NN conj NN + dep NN"
          3 : 1
          4 : 
            {
              1 : "drug5 were positively associated with the risk alleles of IL23R drug1 ( OR = 2.25 [1.13-4.51 ] ) and 6q21 drug2 ( OR = 1.60 [1.10-2.34 ] and negatively associated with the risk alleles of IRGM drug3 ( OR = 0.29 [0.11-0.74 ] ) and DEFB1 drug4 ( OR = 0.50 [0.30-0.80 ] ) . "
            }
          5 : 
            {
              1 : "associated + dep drug0 + ppmod alleles ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NNS ppmod NN conj NN + dep NN"
          2 : "VBN + dep NN + ppmod NNS ppmod NN conj NN"
          3 : 17
          4 : 
            {
              1 : "Caution should be exercised if an drug1 is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as drug2 , drug3 , and drug4 . "
              2 : "drug1 should not be administered concurrently with D2-antagonists , such as drug2 , drug3 , drug4 , or drug5 . "
              3 : "Additive CNS depression may occur when drug1 are administered concomitantly with other drug2 including drug3 , drug4 , and drug5 . "
              4 : "When drug1 is co-administered with inducers of drug clearance , such as drug2 , drug3 , drug4 , drug5 , or drug6 , use of a daily dose of 70 mg of drug7 should be considered "
              5 : "Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes , caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug3 and drug4 or inhibitors of CYP2C19 such as drug5 . "
              6 : "drug1 should not be administered concomitantly with potent drug2 such as drug3 and drug4 as the potential for ototoxicity is enhanced by the combination . "
              7 : "Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window , such as drug2 , drug3 and drug4 ( see CLINICAL PHARMACOLOGY ) . "
              8 : "drug1 should be administered with caution to patients who are taking other drug2 or drug3 , including drug4 , drug5 and drug6 , or to those with a history of psychiatric disorder ( including manic-depressive illness and schizophrenia ) . "
            }
          5 : 
            {
              1 : "administered + ppmod drugs ppmod drug0 conj drug0 + dep drug0"
              2 : "administered + ppmod d0-antagonists ppmod drug0 conj drug0 + dep drug0"
              3 : "administered + ppmod drug0 ppmod drug0 conj drug0 + dep drug0"
              4 : "co-administered + ppmod inducers ppmod drug0 conj drug0 + dep drug0"
              5 : "coadministered + ppmod inhibitors ppmod drug0 conj drug0 + dep drug0"
              6 : "administered + ppmod drug0 ppmod drug0 conj drug0 + dep drug0"
              7 : "used + ppmod medications ppmod drug0 conj drug0 + dep drug0"
              8 : "administered + ppmod patients ppmod drug0 conj drug0 + dep drug0"
            }
        }
    }
  56 : 
    {
      snpphena : 
        {
          1 : "NN + + conj NNS ppmod NN"
          2 : "NN + conj NNS ppmod NN +"
          3 : 1
          4 : 
            {
              1 : "No statistically significant association of the SNPs was observed with drug3 or drug4 or between carriers and non-carriers of drug1 and drug2 mutations . "
            }
          5 : 
            {
              1 : "drug0 + + conj carriers ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + conj NNS ppmod NN +"
          2 : "NN + + conj NNS ppmod NN"
          3 : 2
          4 : 
            {
              1 : "A rare , but serious , constellation of symptoms , termed serotonin syndrome , has been reported with the concomitant use of drug1 ( drug2 ) and agents for migraine therapy , such as drug3 ( drug4 ) and drug5 . "
              2 : "Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications , including drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , and drug11 . "
            }
          5 : 
            {
              1 : "drug0 + conj agents ppmod drug0 +"
              2 : "drug0 + conj medications ppmod drug0 +"
            }
        }
    }
  57 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN conj NN com NN + dep NN"
          2 : "VBN + dep NN + ppmod NN conj NN com NN"
          3 : 1
          4 : 
            {
              1 : "Of the 3 SNPs most significantly associated with MI , drug1 , which defines the Apo E2 isoform , was associated with both a lower Apo B/A1 ratio ( P=1.0x10 ( -7 ) ) and lower drug2 risk ( P=0.0004 ) . "
            }
          5 : 
            {
              1 : "associated + ppmod ratio conj risk com drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN conj NN com NN + dep NN"
          2 : "VBN + dep NN + ppmod NN conj NN com NN"
          3 : 1
          4 : 
            {
              1 : "however , it adversely affected response duration suggesting that drug1 should not be administered with drug2 and/or drug3 .1 "
            }
          5 : 
            {
              1 : "administered + ppmod drug0 conj .0 com drug0 + dep drug0"
            }
        }
    }
  58 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN ppmod NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Our results suggest a possible influence of TCF7L2 drug1 on the risk of drug2 . "
            }
          5 : 
            {
              1 : "influence + ppmod risk ppmod drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN ppmod NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN ppmod NN"
          3 : 20
          4 : 
            {
              1 : "The consumption of drug1 during treatment with drug2 should be minimized or avoided ( also see a href= bupropz_od.htm # CI CONTRAINDICATIONS ) "
              2 : "In an in vitro study in human liver microsomes , inhibition of CYP2A6 hydroxylation of drug1 by drug2 ( 200 m m M i.e. , 350 mg/L ) was 17-28 % . "
              3 : "Co-administration of drug1 at steady-state with a single dose of drug2 ( 2 x 600 mg tablets ) results in increased drug3 serum concentrations . "
              4 : "Therefore , use of drug1 in combination with drug2 is not recommended "
              5 : "It has been reported that the addition of drug1 to a maintenance schedule of drug2 resulted in reversible acute renal failure in two of four healthy volunteers . "
              6 : "However , due to possible pharmacodynamic interactions , when co-administered with drug1 , a reduction in dosage of drug2 on the concomitant drug3 , drug4 , drug5 or drug6 may be required . "
              7 : "The concomitant administration of drug1 including drug2 with drug3 ( a drug4 ) has , on rare occasions , resulted in severe hypoglycemia . "
              8 : "The mechanism for this interaction probably is adsorption of drug1 onto the surface of drug2 . "
              9 : "Particular caution should be observed with drug1 since there are conflicting results for the effect of drug2 on the availability of drug3 and drug4 . "
              10 : "therefore , the efficacy of oral drug1 during administration of drug2 may be reduced . "
            }
          5 : 
            {
              1 : "consumption + ppmod treatment ppmod drug0 + ppmod drug0"
              2 : "inhibition + ppmod drug0 + ppmod hydroxylation ppmod drug0"
              3 : "co-administration + ppmod dose ppmod drug0 + ppmod drug0"
              4 : "use + ppmod combination ppmod drug0 + ppmod drug0"
              5 : "addition + ppmod schedule ppmod drug0 + ppmod drug0"
              6 : "reduction + ppmod drug0 + ppmod dosage ppmod drug0"
              7 : "administration + ppmod drug0 ppmod drug0 + ppmod drug0"
              8 : "adsorption + ppmod surface ppmod drug0 + ppmod drug0"
              9 : "effect + ppmod availability ppmod drug0 + ppmod drug0"
              10 : "efficacy + ppmod administration ppmod drug0 + ppmod drug0"
            }
        }
    }
  59 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN ppmod NN ppmod NN ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN ppmod NN ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The nicotinic acetylcholine receptor polymorphism drug1 on chromosome 15q25 is associated with major drug2 in the general population with additional increased risk of drug3 as well as drug4 . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 ppmod population ppmod risk ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN ppmod NN ppmod NN ppmod NN + dep NN"
          2 : "VBN + dep NN + ppmod NN ppmod NN ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "drug1 may be taken with a light meal 1 h following the administration of 400 mg of drug2 . "
            }
          5 : 
            {
              1 : "taken + ppmod h ppmod administration ppmod mg ppmod drug0 + dep drug0"
            }
        }
    }
  60 : 
    {
      snpphena : 
        {
          1 : "VB + obj NNS ppmod NN + dep NNS attr NN conj NN"
          2 : "VB + dep NNS attr NN conj NN + obj NNS ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Allele G fromCOMT SNPs drug1 and drug2 may represent reliable state-dependent predictors of global drug3 during manic and mixed episodes in drug4 . "
            }
          5 : 
            {
              1 : "represent + obj predictors ppmod drug0 + dep snps attr drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VB + obj NNS ppmod NN + dep NNS attr NN conj NN"
          2 : "VB + dep NNS attr NN conj NN + obj NNS ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Organic drug1 - drug2 supplements theoretically may potentiate the effects of organic drug3 if taken concomitantly . "
            }
          5 : 
            {
              1 : "potentiate + obj effects ppmod drug0 + dep supplements attr drug0 conj drug0"
            }
        }
    }
  61 : 
    {
      snpphena : 
        {
          1 : "NNS + ppmod NN + ppmod NN"
          2 : "NNS + ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Conclusion : This study highlights the gender-specific and weight-sensitive effects of APOA5 drug1 on central drug2 in Taiwanese individuals , and that these effects are dyslipidemia-independent and weight-loss responsive . "
            }
          5 : 
            {
              1 : "effects + ppmod drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NNS + ppmod NN + ppmod NN"
          2 : "NNS + ppmod NN + ppmod NN"
          3 : 4
          4 : 
            {
              1 : "Similarly , the effects of drug1 on drug2 , drug3 and sodium plasma drug4 concentrations are unpredictable "
              2 : "Possible drug interactions of drug1 with drug2 or with other drug3 . "
              3 : "The benefits and risks of using drug1 with drug2 and other potentially nephrotoxic agents should be carefully considered , and the lowest effective dose employed "
              4 : "There have been reports of interactions of drug1 with drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , drug8 , drug9 , drug10 , drug11 , drug12 , drug13 , and drug14 . "
            }
          5 : 
            {
              1 : "effects + ppmod drug0 + ppmod drug0"
              2 : "interactions + ppmod drug0 + ppmod drug0"
              3 : "benefits + ppmod drug0 + ppmod drug0"
              4 : "interactions + ppmod drug0 + ppmod drug0"
            }
        }
    }
  62 : 
    {
      snpphena : 
        {
          1 : "VB + obj NN ppmod NN + dep NNS ppmod NN"
          2 : "VB + dep NNS ppmod NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . "
            }
          5 : 
            {
              1 : "affect + obj prevalence ppmod drug0 + dep variants ppmod drug0"
            }
        }
      full : 
        {
          1 : "VB + obj NN ppmod NN + dep NNS ppmod NN"
          2 : "VB + dep NNS ppmod NN + obj NN ppmod NN"
          3 : 4
          4 : 
            {
              1 : "However , high doses of drug1 may reduce the efficacy of intrathecally administered drug2 . "
              2 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . "
              3 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . "
              4 : "Drugs such as drug1 and drug2 may inhibit the metabolism of drug3 and thus decrease their clearance . "
            }
          5 : 
            {
              1 : "reduce + obj efficacy ppmod drug0 + dep doses ppmod drug0"
              2 : "potentiate + obj action ppmod drug0 + dep drugs ppmod drug0"
              3 : "reduce + obj action ppmod drug0 + dep drugs ppmod drug0"
              4 : "inhibit + obj metabolism ppmod drug0 + dep drugs ppmod drug0"
            }
        }
    }
  63 : 
    {
      snpphena : 
        {
          1 : "VB + obj NN ppmod NN + dep NNS ppmod NN conj NN"
          2 : "VB + dep NNS ppmod NN conj NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Genetic variants of drug1 and drug2 may synergistically affect the prevalence of drug3 in East Asian populations and of drug4 in Japanese individuals . "
            }
          5 : 
            {
              1 : "affect + obj prevalence ppmod drug0 + dep variants ppmod drug0 conj drug0"
            }
        }
      full : 
        {
          1 : "VB + obj NN ppmod NN + dep NNS ppmod NN conj NN"
          2 : "VB + dep NNS ppmod NN conj NN + obj NN ppmod NN"
          3 : 8
          4 : 
            {
              1 : "drug1 : Since drug2 is a drug3 , it is possible that drug4 , such as the drug5 ( drug6 , drug7 , drug8 ) or drug9 , may diminish the effectiveness of drug10 . "
              2 : "Certain drugs , including drug1 ( drug2 ) , drug3 , drug4 , and drug5 may potentiate the hypoglycemic action of drug6 and other oral drug7 . "
              3 : "Certain drugs including drug1 , drug2 , drug3 , and drug4 may reduce the hypoglycemic action of drug5 and other oral drug6 . "
              4 : "Drugs such as drug1 and drug2 may inhibit the metabolism of drug3 and thus decrease their clearance . "
            }
          5 : 
            {
              1 : "diminish + obj effectiveness ppmod drug0 + dep drug0 ppmod drug0 conj drug0"
              2 : "potentiate + obj action ppmod drug0 + dep drugs ppmod drug0 conj drug0"
              3 : "reduce + obj action ppmod drug0 + dep drugs ppmod drug0 conj drug0"
              4 : "inhibit + obj metabolism ppmod drug0 + dep drugs ppmod drug0 conj drug0"
            }
        }
    }
  64 : 
    {
      snpphena : 
        {
          1 : "NN + acl VBN ppmod NN +"
          2 : "NN + + acl VBN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Our haplotype trend analysis identified a drug1 significantly associated with drug2 ( p = .0013 ) , drug3 ( p = .0024 ) , and drug4 ( p = .017 ) . "
            }
          5 : 
            {
              1 : "drug0 + acl associated ppmod drug0 +"
            }
        }
      full : 
        {
          1 : "NN + acl VBN ppmod NN +"
          2 : "NN + + acl VBN ppmod NN"
          3 : 8
          4 : 
            {
              1 : "drug1 used concurrently with drug2 may also result in increased cardiotoxicity . "
              2 : "drug1 given concomitantly with drug2 has been reported to increase the serum concentration and prolong the half-life of drug3 . "
              3 : "drug1 administered concurrently with drug2 reduced the urine volume in 4 healthy volunteers . "
              4 : "Results of preliminary studies in humans and rats suggest that nonabsorbable drug1 given concurrently with drug2 may inhibit the desired drug3 -induced drop in colonic pH . "
              5 : "drug1 : drug2 , given concomitantly with drug3 or 60 minutes following drug4 administration , decreased drug5 bioavailability by approximately 25 % . "
              6 : "drug1 : Animal studies wshow that drug2 given with drug3 , including drug4 , yields a net decrease in anti-inflammatory activity with lowered blood levels of the non-aspirin drug . "
              7 : "drug1 : drug2 , given concomitantly with drug3 , produces a reduction in urinary potassium and chloride excretion compared to drug4 alone . "
              8 : "drug1 - and drug2 -containing drug3 , administered concomitantly with drug4 , significantly decreased the bioavailability ( 48 % ) of drug5 . "
            }
          5 : 
            {
              1 : "drug0 + acl used ppmod drug0 +"
              2 : "drug0 + acl given ppmod drug0 +"
              3 : "drug0 + acl administered ppmod drug0 +"
              4 : "drug0 + acl given ppmod drug0 +"
              5 : "drug0 + acl given ppmod drug0 +"
              6 : "drug0 + acl given ppmod drug0 +"
              7 : "drug0 + acl given ppmod drug0 +"
              8 : "drug0 + acl administered ppmod drug0 +"
            }
        }
    }
  65 : 
    {
      snpphena : 
        {
          1 : "VBD + ppmod NN + dep NN ppmod NN"
          2 : "VBD + dep NN ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The frequency of the A genotype in PLCH1 drug1 occurred more frequently in drug2 than in controls ( P = .02 ) . "
            }
          5 : 
            {
              1 : "occurred + ppmod drug0 + dep frequency ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBD + ppmod NN + dep NN ppmod NN"
          2 : "VBD + dep NN ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Concomitant administration of drug1 doubled the AUC for drug2 . "
            }
          5 : 
            {
              1 : "doubled + ppmod drug0 + dep administration ppmod drug0"
            }
        }
    }
  66 : 
    {
      snpphena : 
        {
          1 : "NNS + ppmod NN ppmod NN + ppmod NN"
          2 : "NNS + ppmod NN + ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "There were also no significant effects of drug1 or E4 carriers on the development of drug2 , but multivariate logistic regression testing revealed that the duration of drug3 and triglyceride and hemoglobin A1c concentrations had independent effects on the development of drug4 . "
            }
          5 : 
            {
              1 : "effects + ppmod development ppmod drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NNS + ppmod NN ppmod NN + ppmod NN"
          2 : "NNS + ppmod NN + ppmod NN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "While the effects of chronic drug1 or drug2 therapy on the action of drug3 are unknown , slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher . "
              2 : "There are rare reports , however , from marketing experiences , of changes in effects of drug1 or oral drug2 in the presence of drug3 that necessitated changes in the doses of such agents . "
            }
          5 : 
            {
              1 : "effects + ppmod action ppmod drug0 + ppmod drug0"
              2 : "effects + ppmod presence ppmod drug0 + ppmod drug0"
            }
        }
    }
  67 : 
    {
      snpphena : 
        {
          1 : "VBN + comp VB obj NN ppmod NN + dep NN"
          2 : "VBN + dep NN + comp VB obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "CONCLUSIONS : drug1 was seen to show a decreased risk for drug2 in Asian population "
            }
          5 : 
            {
              1 : "seen + comp show obj risk ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + comp VB obj NN ppmod NN + dep NN"
          2 : "VBN + dep NN + comp VB obj NN ppmod NN"
          3 : 13
          4 : 
            {
              1 : "drug1 has been reported to decrease the tubular secretion of drug2 and to potentiate its toxicity . "
              2 : "drug1 , drug2 and other drug3 have been reported to reduce the tubular secretion of drug4 in an animal model , possibly increasing the toxicity of drug5 . "
              3 : "Interactions for drug1 ( drug2 , drug3 , drug4 , and drug5 ) : drug6 : drug7 has been reported to reduce intestinal absorption of drug8 ; "
              4 : "drug1 have been reported to decrease the tubular secretion of drug2 and to potentiate its toxicity . "
              5 : "drug1 , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of drug2 , drug3 , drug4 , drug5 , drug6 , drug7 , certain drug8 , drug9 , drug10 and drug11 , thereby delaying elimination and increasing blood levels of these drugs . "
              6 : "drug1 have been reported to blunt the hypotensive effect of systemic drug2 . "
              7 : "drug1 has been shown to induce the metabolism of drug2 and drug3 , which are metabolized through CYP2C9 . "
              8 : "drug1 has been reported to decrease the clearance of drug2 and drug3 and thus may increase the pharmacologic effect of these drug4 . "
              9 : "drug1 has been reported to significantly alter the metabolism of nonsedating drug2 drug3 and drug4 when taken concomitantly . "
              10 : "Interactions for drug1 analogues ( drug2 , drug3 , drug4 , and drug5 ) : drug6 : drug7 has been reported to reduce intestinal absorption of drug8 ; "
            }
          5 : 
            {
              1 : "reported + comp decrease obj secretion ppmod drug0 + dep drug0"
              2 : "reported + comp reduce obj secretion ppmod drug0 + dep drug0"
              3 : "reported + comp reduce obj absorption ppmod drug0 + dep drug0"
              4 : "reported + comp decrease obj secretion ppmod drug0 + dep drug0"
              5 : "reported + comp reduce obj metabolism ppmod drug0 + dep drug0"
              6 : "reported + comp blunt obj effect ppmod drug0 + dep drug0"
              7 : "shown + comp induce obj metabolism ppmod drug0 + dep drug0"
              8 : "reported + comp decrease obj clearance ppmod drug0 + dep drug0"
              9 : "reported + comp alter obj metabolism ppmod drug0 + dep drug0"
              10 : "reported + comp reduce obj absorption ppmod drug0 + dep drug0"
            }
        }
    }
  68 : 
    {
      snpphena : 
        {
          1 : "VBZ + ppmod NN ppmod NN + dep NN"
          2 : "VBZ + dep NN + ppmod NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "In conclusion , our findings provide evidence that in addition to other genes , drug1 also has a significant role in the development of drug2 , and demonstrate that analysing the complex phenotype associations of genes by haplotype tagging is a powerful method . "
            }
          5 : 
            {
              1 : "has + ppmod development ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBZ + ppmod NN ppmod NN + dep NN"
          2 : "VBZ + dep NN + ppmod NN ppmod NN"
          3 : 7
          4 : 
            {
              1 : "drug1 : drug2 interferes with renal tubular secretion of drug3 and produces an increase in the level of drug4 in serum . "
              2 : "drug1 : drug2 causes increase ( by about 80 % ) in the free fraction of drug3 . "
              3 : "drug1 also has no significant effect on the intracellular phosphorylation of drug2 , as shown in vitro in peripheral blood mononuclear cells or in two other cell lines ( U937 and Molt-4 ) . "
              4 : "drug1 interferes with the metabolism of drug2 resulting in a 42 % to 74 % dose-related decrease in drug3 clearance and a subsequent 260 % to 350 % increase in serum theophylline levels . "
              5 : "drug1 interferes with the therapeutic action of drug2 . "
              6 : "drug1 interferes with the absorption of drug2 , including drug3 . "
              7 : "drug1 protects mouse tumour and normal tissues from the toxicity of oral drug2 . "
            }
          5 : 
            {
              1 : "interferes + ppmod secretion ppmod drug0 + dep drug0"
              2 : "causes + ppmod fraction ppmod drug0 + dep drug0"
              3 : "has + ppmod phosphorylation ppmod drug0 + dep drug0"
              4 : "interferes + ppmod metabolism ppmod drug0 + dep drug0"
              5 : "interferes + ppmod action ppmod drug0 + dep drug0"
              6 : "interferes + ppmod absorption ppmod drug0 + dep drug0"
              7 : "protects + ppmod toxicity ppmod drug0 + dep drug0"
            }
        }
    }
  69 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NNS ppmod NN conj NN + ppmod NN com NN"
          2 : "NN + ppmod NN com NN + ppmod NNS ppmod NN conj NN"
          3 : 1
          4 : 
            {
              1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . "
            }
          5 : 
            {
              1 : "involvement + ppmod genetics ppmod drug0 conj drug0 + ppmod locus com drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS ppmod NN conj NN + ppmod NN com NN"
          2 : "NN + ppmod NN com NN + ppmod NNS ppmod NN conj NN"
          3 : 2
          4 : 
            {
              1 : "The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity , such as drug3 , drug4 , or drug5 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects . "
            }
          5 : 
            {
              1 : "use + ppmod drug0 ppmod drug0 conj drug0 + ppmod injection com drug0"
            }
        }
    }
  70 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NNS ppmod NN + ppmod NN com NN"
          2 : "NN + ppmod NN com NN + ppmod NNS ppmod NN"
          3 : 1
          4 : 
            {
              1 : "CONCLUSIONS : Although the physiological role of drug1 in drug3 and drug4 needs further investigations , our results suggest an involvement of the drug2 gene locus in the genetics of drug5 and drug6 . "
            }
          5 : 
            {
              1 : "involvement + ppmod genetics ppmod drug0 + ppmod locus com drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NNS ppmod NN + ppmod NN com NN"
          2 : "NN + ppmod NN com NN + ppmod NNS ppmod NN"
          3 : 1
          4 : 
            {
              1 : "The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity , such as drug3 , drug4 , or drug5 , may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects . "
            }
          5 : 
            {
              1 : "use + ppmod drug0 ppmod drug0 + ppmod injection com drug0"
            }
        }
    }
  71 : 
    {
      snpphena : 
        {
          1 : "VBP + obj NN ppmod NN + dep NN"
          2 : "VBP + dep NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Our results support the hypothesis that drug1 influence the prevalence of drug2 and possibly overweight in drug3 patients . "
            }
          5 : 
            {
              1 : "influence + obj prevalence ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBP + obj NN ppmod NN + dep NN"
          2 : "VBP + dep NN + obj NN ppmod NN"
          3 : 10
          4 : 
            {
              1 : "- drug1 and drug2 drug3 : drug4 and drug5 drug6 have the potential of binding drug7 and reducing drug8 absorption from the gastrointestinal tract "
              2 : "drug1 reduce the renal clearance of drug2 and add a high risk of drug3 toxicity . "
              3 : "drug1 : In vitro and/or in vivo data show that drug2 , drug3 , and drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . "
              4 : "drug1 : In vitro and/or in vivo data indicate that drug2 , drug3 , and oral drug4 markedly inhibit the metabolism of drug5 , which can result in an increase in plasma drug6 levels and prolongation of the QT interval on the ECG . "
              5 : "drug1 : In vitro data indicate that drug2 and drug3 markedly inhibit the metabolism of drug4 which can result in an increase in plasma drug5 levels and prolongation of the QT interval on the ECG . "
              6 : "drug1 , drug2 , and drug3 decrease the ED50 of drug4 by 30 % to 45 % . "
              7 : "drug1 : drug2 , including drug3 , decrease the clearance of drug4 , the less active isomer of racemic drug5 . "
              8 : "drug1 , drug2 , and drug3 decrease the half-life of drug4 . "
              9 : "drug1 decrease the hypotensive effect of drug2 . "
            }
          5 : 
            {
              1 : "have + obj potential ppmod drug0 + dep drug0"
              2 : "reduce + obj clearance ppmod drug0 + dep drug0"
              3 : "inhibit + obj metabolism ppmod drug0 + dep drug0"
              4 : "inhibit + obj metabolism ppmod drug0 + dep drug0"
              5 : "inhibit + obj metabolism ppmod drug0 + dep drug0"
              6 : "decrease + obj ed0 ppmod drug0 + dep drug0"
              7 : "decrease + obj clearance ppmod drug0 + dep drug0"
              8 : "decrease + obj half-life ppmod drug0 + dep drug0"
              9 : "decrease + obj effect ppmod drug0 + dep drug0"
            }
        }
    }
  72 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN conj NN prn NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN conj NN prn NN"
          3 : 1
          4 : 
            {
              1 : "OBJECTIVE : We aimed to replicate the association of the drug1 ( IVS3C/T ) and drug2 ( IVS3C/T ) polymorphisms of transcription factor 7-like 2 ( TCF7L2 ) and drug3 ( drug4 ) in Han Chinese people in Henan province , China . "
            }
          5 : 
            {
              1 : "association + ppmod factor conj drug0 prn drug0 + ppmod drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN conj NN prn NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN conj NN prn NN"
          3 : 1
          4 : 
            {
              1 : "Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g. , intravenous drug2 ( e.g. , drug3 , drug4 , and drug5 ) , drug6 , drug7 , intravenous drug8 , drug9 , and drug10 ] is contraindicated . "
            }
          5 : 
            {
              1 : "administration + ppmod [e.g. conj drug0 prn drug0 + ppmod drug0"
            }
        }
    }
  73 : 
    {
      snpphena : 
        {
          1 : "VB + obj NN ppmod NN + dep NN com NN"
          2 : "VB + dep NN com NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "GAB2 drug1 marker does not modify the risk of drug2 in Spanish APOE epsilon 4 carriers . "
            }
          5 : 
            {
              1 : "modify + obj risk ppmod drug0 + dep marker com drug0"
            }
        }
      full : 
        {
          1 : "VB + obj NN ppmod NN + dep NN com NN"
          2 : "VB + dep NN com NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "drug1 or drug2 excess may decrease the effect of drug3 , and an drug4 deficiency can increase the effect of drug5 . "
            }
          5 : 
            {
              1 : "increase + obj effect ppmod drug0 + dep deficiency com drug0"
            }
        }
    }
  74 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN com NN + dep NNS ppmod NN"
          2 : "VBN + dep NNS ppmod NN + ppmod NN com NN"
          3 : 1
          4 : 
            {
              1 : "In this study , we investigated whether variants in three key pigmentation genes- drug1 , drug2 , and drug3 --were involved in drug4 predisposition "
            }
          5 : 
            {
              1 : "involved + ppmod predisposition com drug0 + dep variants ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + dep NNS ppmod NN + ppmod NN com NN"
          2 : "VBN + ppmod NN com NN + dep NNS ppmod NN"
          3 : 3
          4 : 
            {
              1 : "With oral drug1 treatment , drug2 such as drug3 have been noted to possibly increase the likelihood of hematologic reactions "
              2 : "Elevated plasma levels of drug1 have been reported with concomitant drug2 use . "
            }
          5 : 
            {
              1 : "noted + dep drug0 ppmod drug0 + ppmod treatment com drug0"
              2 : "reported + ppmod use com drug0 + dep levels ppmod drug0"
            }
        }
    }
  75 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NNS com NN"
          2 : "VBN + dep NNS com NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "CONCLUSIONS : drug1 haplotypes are significantly associated with drug2 in our population . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep haplotypes com drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NNS com NN"
          2 : "VBN + dep NNS com NN + ppmod NN"
          3 : 4
          4 : 
            {
              1 : "drug1 : drug2 is known to slow the metabolism of drug3 and increase its serum levels drug4 levels should be determined prior to concurrent administration with drug5 , signs and symptoms of drug6 toxicity should be monitored closely , and appropriate dosage adjustment of the drug7 should be made . "
              2 : "drug1 effects are potentiated by drug2 . "
              3 : "Therefore , close monitoring of prothrombin time is recommended and adjustment of the drug1 dose may be necessary when drug2 Capsules are administered concomitantly with drug3 . "
              4 : "drug1 : Serum drug2 levels may be increased by drug3 . "
            }
          5 : 
            {
              1 : "determined + ppmod drug0 + dep levels com drug0"
              2 : "potentiated + ppmod drug0 + dep effects com drug0"
              3 : "administered + ppmod drug0 + dep capsules com drug0"
              4 : "increased + ppmod drug0 + dep levels com drug0"
            }
        }
    }
  76 : 
    {
      snpphena : 
        {
          1 : "VBN + comp VBN ppmod NN + dep NN"
          2 : "VBN + dep NN + comp VBN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "drug1 , SFA intake , and drug2 were found to be associated with drug3 in Lithuanian adult population . "
            }
          5 : 
            {
              1 : "found + comp associated ppmod drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBN + comp VBN ppmod NN + dep NN"
          2 : "VBN + dep NN + comp VBN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "drug1 and drug2 use may be rarely associated with ventricular fibrillation when combined with drug3 . "
              2 : "The clinical significance of this reduction is not known , hence drug1 is not recommended to be ingested simultaneously with drug2 / drug3 -containing drug4 . "
            }
          5 : 
            {
              1 : "associated + comp combined ppmod drug0 + dep drug0"
              2 : "recommended + comp ingested ppmod drug0 + dep drug0"
            }
        }
    }
  77 : 
    {
      snpphena : 
        {
          1 : "VBN + ppmod NN + dep NNS ppmod NN"
          2 : "VBN + dep NNS ppmod NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Genotypes at drug1 were not associated with any drug2 . "
            }
          5 : 
            {
              1 : "associated + ppmod drug0 + dep genotypes ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBN + ppmod NN + dep NNS ppmod NN"
          2 : "VBN + dep NNS ppmod NN + ppmod NN"
          3 : 11
          4 : 
            {
              1 : "Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach : Drugs such as drug1 and drug2 should be administered at least 2 hours prior to dosing with drug3 . "
              2 : "The effects of drug1 may be potentiated by drug2 which inhibits the metabolism of drug3 . "
              3 : "The pressor effects of drug1 such as drug2 or drug3 are enhanced by drug4 . "
              4 : "Cardiac effects of drug1 are antagonized by drug2 , such as drug3 and drug4 . "
              5 : "The actions of the drug1 may be potentiated by drug2 , drug3 , drug4 , drug5 or other drug6 . "
              6 : "Effects of drug1 are increased with drug2 and drug3 . "
              7 : "The antihypertensive effects of drug1 , drug2 , drug3 , and drug4 may be reduced by drug5 . "
              8 : "The CNS effects of drug1 may be enhanced by drug2 . "
              9 : "In monkeys , the effects of drug1 , but not drug2 or drug3 , were antagonized by drug4 ; "
            }
          5 : 
            {
              1 : "administered + ppmod drug0 + dep drugs ppmod drug0"
              2 : "potentiated + ppmod drug0 + dep effects ppmod drug0"
              3 : "enhanced + ppmod drug0 + dep effects ppmod drug0"
              4 : "antagonized + ppmod drug0 + dep effects ppmod drug0"
              5 : "potentiated + ppmod drug0 + dep actions ppmod drug0"
              6 : "increased + ppmod drug0 + dep effects ppmod drug0"
              7 : "reduced + ppmod drug0 + dep effects ppmod drug0"
              8 : "enhanced + ppmod drug0 + dep effects ppmod drug0"
              9 : "antagonized + ppmod drug0 + dep effects ppmod drug0"
            }
        }
    }
  78 : 
    {
      snpphena : 
        {
          1 : "NNS + ppmod NN + appo NN"
          2 : "NNS + appo NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "the minor alleles of cholesteryl ester transfer protein ( CETP ) gene SNPs drug1 and drug2 were associated with drug12 and drug3 with drug13 ; CETP SNPs drug4 , drug5 , and drug6 and apolipoprotein B ( APOB ) gene SNP drug7 with drug14 ; APOE SNP drug8 , peroxisome proliferator-activated receptor gamma ( PPARG ) gene SNP drug9 with drug15 , and CETP SNP drug10 with drug16 ; and APOE/C1/C4/C2 cluster SNP drug11 with lower serum TG . "
            }
          5 : 
            {
              1 : "snps + ppmod drug0 + appo drug0"
            }
        }
      full : 
        {
          1 : "NNS + ppmod NN + appo NN"
          2 : "NNS + appo NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "Patients receiving other drug1 s , general drug2 , drug3 , drug4 , drug5 , drug6 or other drug7 ( including drug8 ) concomitantly with drug9 may exhibit an additive CNS depression . "
            }
          5 : 
            {
              1 : "patients + ppmod drug0 + appo drug0"
            }
        }
    }
  79 : 
    {
      snpphena : 
        {
          1 : "VBD + obj NN ppmod NN prn NN + dep NN"
          2 : "VBD + dep NN + obj NN ppmod NN prn NN"
          3 : 1
          4 : 
            {
              1 : "However , drug1 showed association with 30 ' Deltainsulin ( drug2 ) in an interaction with percentage of body fat ( Bonferroni-corrected P = 0.027 ) . "
            }
          5 : 
            {
              1 : "showed + obj association ppmod deltainsulin prn drug0 + dep drug0"
            }
        }
      full : 
        {
          1 : "VBD + obj NN ppmod NN prn NN + dep NN"
          2 : "VBD + dep NN + obj NN ppmod NN prn NN"
          3 : 1
          4 : 
            {
              1 : "drug1 decreased the Cmax and AUC of sustained-release drug2 ( drug3 ) by approximately 31 % and 11 % , respectively . "
            }
          5 : 
            {
              1 : "decreased + obj cmax ppmod drug0 prn drug0 + dep drug0"
            }
        }
    }
  80 : 
    {
      snpphena : 
        {
          1 : "VBP + obj NN ppmod NN + dep NN ppmod NN"
          2 : "VBP + dep NN ppmod NN + obj NN ppmod NN"
          3 : 1
          4 : 
            {
              1 : "In conclusion , the T allele of the drug1 and drug2 polymorphisms of TCF7L2 gene confer susceptibility to drug3 in Asian Indians . "
            }
          5 : 
            {
              1 : "confer + obj susceptibility ppmod drug0 + dep allele ppmod drug0"
            }
        }
      full : 
        {
          1 : "VBP + obj NN ppmod NN + dep NN ppmod NN"
          2 : "VBP + dep NN ppmod NN + obj NN ppmod NN"
          3 : 2
          4 : 
            {
              1 : "drug1 : drug2 , including drug3 , decrease the clearance of drug4 , the less active isomer of racemic drug5 . "
              2 : "These results suggest that exposure to environmental drug1 may alter the biological and behavioral responsiveness of an animal to drug2 . "
            }
          5 : 
            {
              1 : "decrease + obj clearance ppmod drug0 + dep drug0 ppmod drug0"
              2 : "alter + obj responsiveness ppmod drug0 + dep exposure ppmod drug0"
            }
        }
    }
  81 : 
    {
      snpphena : 
        {
          1 : "NN + ppmod NN + ppmod NN conj NNS com NN"
          2 : "NN + ppmod NN conj NNS com NN + ppmod NN"
          3 : 1
          4 : 
            {
              1 : "We studied the effect of TCF7L2 drug1 and drug2 genotypes on drug3 "
            }
          5 : 
            {
              1 : "effect + ppmod drug0 + ppmod drug0 conj genotypes com drug0"
            }
        }
      full : 
        {
          1 : "NN + ppmod NN conj NNS com NN + ppmod NN"
          2 : "NN + ppmod NN + ppmod NN conj NNS com NN"
          3 : 2
          4 : 
            {
              1 : "Use of drug1 with drug2 ( e.g. , drug3 , drug4 , or drug5 ) , drug6 supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium . "
              2 : "Acid-catalyzed ethanolysis of drug1 in anhydrous and aqueous drug2 solutions . "
            }
          5 : 
            {
              1 : "use + ppmod drug0 conj supplements com drug0 + ppmod drug0"
              2 : "ethanolysis + ppmod anhydrous conj solutions com drug0 + ppmod drug0"
            }
        }
    }
}